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8 General introduction 
A dramatic increase in mean and maximal life span, coupled with a significant reduction in early 
mortality has lead to a large increase in the number of elderly people in modern societies. 
Progression of age is associated with a reduction of the response to environmental stimuli and, in 
general, is associated with an increased predisposition to illness and death. The high incidence of 
death due to infections, cardiovascular disease, and cancer underlies a common feature in these 
pathologies that is represented by dysregulation of both systemic and innate immunity (1). Ageing 
is accompanied by a chronic low-grade inflammation state clearly showed by 2-4-fold increase in 
serum levels of pro-inflammatory mediators (2). This pro-inflammatory state, interacting with the 
genetic background, potentially triggers the onset of age-related inflammatory diseases like 
atherosclerosis, dementia, and cancer (1). Genetic epidemiology is an important tool to investigate 
the association between innate immunity and age-related diseases. 
 
Inflammation and cardiovascular disease 
Atherosclerosis, a progressive disease characterized by the accumulation of lipid and fibrous 
elements in the large arteries, is the most important contributor of cardiovascular disease (3). 
Advances in medical science have established a fundamental role for inflammation in mediating all 
stages of atherosclerosis from initiation through progression (4-6). For example, macrophages and 
blood leucocytes, mediators of host defenses and inflammation, are found in the earliest lesions of 
atherosclerosis. Macrophage-derived foam cells and leucocytes drive lesion progression by 
secreting inflammatory stimuli (7).    
 
Inflammatory stimuli, like the pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis 
factor-alpha (TNFα), are implicated in the development of atherosclerosis (6;8). IL-6 stimulates 
endothelial activation, vascular smooth muscle cell proliferation and leucocyte recruitment, all of 
which lead to plaque growth or instability. Major effects of TNFα on the cardiovascular system 
include increased expression of adhesion molecules, release of endothelial cytokines and nitric 
oxide, and enhanced vascular permeability. Another pro-inflammatory cytokine is lymphotoxin-
alpha (LTA), also known as tumor necrosis factor beta (TNFβ), which activates a cytokine cascade 
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by inducing IL-1 (9;10). LTA is expressed in atherosclerotic lesions and induces the expression of a 
number of molecules involved in atherogenesis (11;12). Moreover, atherosclerotic lesions in LTA 
knock-out mice are significantly smaller compared to LTA wild-type mice (12).  
 
Besides these pro-inflammatory cytokines, anti-inflammatory cytokines like IL-10 may also play a 
role in the development of atherosclerosis (13). In IL-10 knockout mice, the absence of IL-10 leads 
to a marked increase in susceptibility of atherosclerosis (14). Furthermore, after occlusion of the 
middle cerebral artery, brain infarcts in IL-10 knockout mice are 30% larger compared to wild-type 
mice (15). However, the contribution of IL-10 to the modulation of the atherosclerotic process in 
humans remains largely to be elucidated. 
 
Inflammation and cognitive function 
Inflammation plays also an important role in the development of cognitive decline and dementia in 
old age (16). There is abundant evidence that inflammatory mechanisms contribute to cognitive 
impairment via cytokine-mediated interactions (16). Animal models expressing high levels of pro-
inflammatory cytokines in the brain suffer from neurodegeneration (17). Furthermore, up-regulation 
of pro-inflammatory cytokines in tissue cultures leads to microglial activation and neuronal damage 
(18) and moreover, several markers of inflammation have been found in and around senile plaques 
in the brain (19). 
 
The interleukin-1 signaling pathway is likely to have a prominent role in the development of 
cognitive decline and dementia (20-23). For example, in rodents peripheral administration of 
interleukin-1beta (IL-1β) induces various cognitive-behavioral effects (20). Furthermore, expression 
of IL-1β is increased in patients with Alzheimer’s disease (22). One of the possible mechanisms by 
which IL-1β acts on cognitive function is by binding to IL-1 type-1 receptors which are abundantly 
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It has been shown that patients with sporadic Alzheimer’s disease have lower IL-10 serum levels 
compared to healthy controls (24;25). Various studies have also investigated the association 
between genetic variation in the IL-10 gene and Alzheimer’s disease (24;26-30). The majority of 
the studies found that the prevalences of variant alleles of IL-10 promoter polymorphisms, 
determinants of low IL-10 production capacity, were increased in patients with Alzheimer’s disease 
compared to healthy controls (24;26;27;30). This indicates that besides pro-inflammatory processes 
also anti-inflammatory processes play a role in cognitive function and dementia in old age.   
 
Inflammation and cancer 
Cancer is now generally accepted as an age-related disease. In fact, incidence and mortality rates of 
most cancers increase consistently with age up to 90 years. Inflammatory responses are also thought 
to be critical in many aspects of promoting the growth and spread of cancers (31). Various studies 
support the hypothesis that inflammatory stimuli, like the pro-inflammatory cytokines IL-6, IL-1β, 
and TNFα, are involved in cancer pathogenesis (32-35). Moreover, elevated levels of various 
cytokines, like IL-1, IL-6, TNFα, fibroblast growth factor (FGF), and transforming growth factor 
(TGF) have been found in blood, urine, and ascites of cancer patients, suggesting that these 
cytokines are involved in incidence and growth and spread of cancer (36). 
 
A recent study showed that cell lines of Lewis lung carcinoma had an increased production of the 
pro-inflammatory cytokines IL-6 and TNFα through activation of the Toll-like receptor (TLR) 
family members TLR2 and TLR6 (37). Moreover, pro-inflammatory cytokines are also involved in 
promoting tumor cell adhesion in metastatic sites which then activate local normal cells to produce 
tumor growth factors (36). Distant-site metastases are the leading cause of cancer-associated 
mortality. Furthermore, animal studies have suggested a role for pro-inflammatory cytokines in the 
generation of cancer-associated cachexia, which is the most important cause of morbidity among 
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Genetic risk factors 
Various studies have reported only moderate associations between inflammatory markers and 
cognitive decline (20;23;41). Therefore, systemic markers are unlikely to be useful as risk 
predictors for cognitive decline (42). On the contrary, genetic variation in inflammatory genes is 
more likely to be a good marker for risk prediction, especially since associations between genetic 
variation and cognitive function are assumed to be unconfounded (43). Moreover, uncertainty exists 
whether levels of cytokines are risk factors for cognitive decline or whether they are a consequence 
of cognitive decline. Functional polymorphisms determine the level of cytokine plasma levels, 
therefore genetic variation can be used as useful marker to overcome this problem of reverse 
causality.   
 
The innate production capacity of inflammatory markers has been shown to be under tight genetic 
control. An extended twin study found that over 50% of the variance in production capacity of 
cytokines is explained by genetic factors (44). IL-1 receptor antagonist (IL-1Ra) and TNFα had the 
lowest heritability (53%), IL-6 and IL-10 had a heritability of 57 and 62% respectively, whereas IL-
1β had the highest heritability (86%). The gene encoding for interleukin-1β-converting enzyme 
(ICE) is likely to be one of the main genes influencing IL-1β. ICE mediates the cleavage of the 
inactive precursor of IL-1β into the biologically active form (45). Inhibition of ICE decreases the 
age-related increase in IL-1β levels (45). Genetic variation in the ICE gene is likely to be functional 
since patients with the 5352AA genotype in the ICE gene have an increased risk of developing 
restenosis after percutaneous coronary intervention, a process where inflammation plays a major 
role (46). Genotypic variation in the IL-10 gene is associated with significantly lower IL-10 
responsiveness upon stimulation with bacterial lipopolysaccharide (LPS) (47). Since genetic 
variation in the promoter region of the IL-10 gene influences the production levels of IL-10, this 
variation can also be related to cardiovascular disease and/or cognitive function.   
  
Other studies have also shown that genetic variation in genes involved in inflammatory processes 
are associated with vascular disease, like myocardial infarction (MI) and stroke (11;48-52). For 
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example, reports have appeared on the association between the LTA C804A polymorphism and the 
severity of atherosclerosis in patients with coronary artery disease (11). This indicates that genetic 
variation in genes involved in inflammation can lead to an increased risk for cardiovascular disease.  
 
Epigenetics and ageing 
While the relationship between inflammation and ageing has been widely investigated, other 
possible mechanisms influencing the progress of ageing and age-related diseases are not well 
understood. One of these mechanisms is epigenetics, the study of heritable changes in gene 
expression that occurs without a change in the sequence of DNA (53-56). The best known 
epigenetic modifications are DNA methylation and post-transcriptional histone modifications, 
including methylation, acetylation, ubiquitylation and phosphorylation. An increased DNA 
methylation will lead to less gene expression, whereas increased histone acetylation will lead to 
more gene expression. Recently it has been shown that aged organisms have modified epigenetic 
features. The best understood epigenetic modification in relation to age-related diseases is that of 
DNA methylation in relation with cancer (53). In cancer cells it is well established that DNA 
methylation patterns are abnormal. More specifically, a global state of hypomethylation is observed, 
along with a hypermethylation state in many gene promoters. In various malignancies an increased 
promoter methylation of the adhesion molecule E-cadherin, an important tumor suppressor, is 
observed. As a result, the hypermethylation state leads to the loss of expression of E-cadherin 
resulting in a predisposition to develop cancer. 
 
Moreover, epigenetic processes modulate gene expression patterns and have profound effects on the 
cellular repertoire of expressed genes. Therefore, epigenetic regulators involved in histone 
acetylating and deacetylating activities can play an important role in extracellular matrix formation, 
inflammation, and proliferation, processes involved in cardiovascular pathologies such as 
atherosclerosis and restenosis (57;58). Another argument that epigenetics could play a role in the 
pathology of cardiovascular disease comes from the Dutch Hunger Winter Study. Subjects who 
were prenatally exposed to a period of famine during World War II had 5.2% less DNA methylation 
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of the IGF2 gene compared to their unexposed sibling (59). Furthermore, subjects exposed to 
famine during gestation had a higher cumulative incidence of coronary artery disease and an earlier 
onset of coronary heart disease compared to unexposed subjects (60). These two findings together 
indicate that changes in epigenetic information can play a role in the pathology of complex diseases 
like cardiovascular disease. Hence, epigenetics can help to explain the relationship between an 
individual’s genetic background, the environment, ageing, and disease. Therefore, active 
investigations continue into potential functional relationships between epigenetic changes and 
disease pathology of age-related diseases.  
 
Mendelian Randomization 
One of the aims of observational research is to identify causes of disease. However, observational 
research has had several high-profile failures when risk factors of disease that were identified in 
observational studies were later shown to be non-causal in randomised controlled trials. Reasons for 
such failures include confounding or disturbance by reverse causality. Genetic epidemiology can 
contribute to establishing the causal nature of environmentally modifiable risk factors, through the 
application of Mendelian randomization approaches (43;61;62). Or in other words, Mendelian 
randomization provides an alternative way of dealing with the problem of causal inference that is 
inherent to observational studies (63).  
 
This new genetic epidemiological tool is based on Mendel’s law that inheritance of one trait is 
independent of inheritance of other traits. This means that the association between a genetically 
determined phenotypic trait and a disease is not susceptible to reverse causality or confounding, 
provided that the presence of the genotype that causes the trait does not influence the subject’s 
lifestyle or environment. This condition will usually be fulfilled as long as subjects are unaware of 
their genotype. 
There are three key assumptions for a genetic variant to be met before they can be used in 
Mendelian randomization (63). First, the genetic variant is associated with the exposure of interest. 
Second, the genetic variant is unrelated to all confounding factors and third, there is no effect of the 
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genetic variant on the outcome or any other mediated effect other than through the exposure of 







Figure 1: Graphical representation of the Mendelian randomization concept. 
 
In 1986 Katan was the first to propose to investigate the causality of cholesterol in the relation with 
cancer by making use of genetic variation in the Apolipoprotein E (ApoE) gene (64). Observational 
studies had shown a relationship between low plasma cholesterol levels and an increased risk for 
cancer. However, randomized clinical trials with cholesterol lowering medications have not shown 
an increased risk for cancer (65). The results of the observational studies could be the result of 
confounding or reverse causality since cholesterol levels could also be lowered by the presence of 
latent tumours. The ApoE gene is known to affect plasma cholesterol levels, with rising cholesterol 
levels from isoform E2 to E3 to E4. Katan’s idea was that individuals carrying the ApoE2 will 
naturally have lower plasma cholesterol levels from birth and that if naturally low cholesterol 
favours tumour growth, carriers of the ApoE2+ genotype should have an increased risk of cancer 
(64). This proposal constituted a prime example of what would later be named Mendelian 
randomization (66;67).  
 
General objective 
The general objective of this thesis was to investigate associations between variants in genes 
involved in inflammation and epigenetics and age-related diseased at old age to get more insights in 
the patho-physiological mechanisms involved in age-related diseases like cardiovascular disease, 
Z X Y
U Z = Genetic variation 
X = Exposure of interest 
Y = Outcome 
U = Possible confounders 
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dementia, and cancer. For all analyses we used data of the participants of the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER).  
 
The aim of PROSPER was to determine whether therapy with pravastatin, a cholesterol-lowering 
medication, would have a beneficial effect on cardiovascular disease risk in an elderly population. 
The PROSPER study was a multicenter, double-blind, placebo-controlled trial of pravastatin against 
placebo in 70-82 year old men and women with either pre-existing vascular disease or at elevated 
risk of such disease due to smoking, hypertension or diabetes. Between December 1997 and May 
1999, subjects were screened and enrolled in Scotland (Glasgow), Ireland (Cork), and the 
Netherlands (Leiden). A total number of 5804 subjects were randomly assigned to pravastatin or 
placebo. The trial concluded that pravastatin given for three years reduces the risk of coronary heart 
disease in the elderly. However, no beneficial effect of pravastatin was found on occurrence of 
stroke and cognitive performance. Therefore, cholesterol-lowering treatment with pravastatin is also 
recommended in the elderly for preventing coronary heart disease. 
 
Aim of this thesis 
First we present five studies investigating the association between genetic variation in inflammation 
related genes and age-related diseases like cardiovascular disease, cognitive decline, and cancer. In 
chapter 2 and 3 we assessed the relation between genetic variation in pro- and anti-inflammatory 
genes and cardiovascular disease. We first assessed the association between LTA and the risk of 
clinical stroke (chapter 2) and then the association between four promoter polymorphisms in the 
anti-inflammatory IL-10 gene and cardiovascular disease (chapter 3). In chapter 4 and 5 the results 
of the association between genetic variation in inflammatory genes and cognitive function are 
shown. We investigated the association between genetic variation in the ICE gene and cognitive 
function in chapter 4 and the relation between genetic variation in the anti-inflammatory IL-10 gene 
and cognitive function in chapter 5. In chapter 6 we describe the relation between pro-inflammatory 
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Second, we describe two studies investigating the relation between genetic variation in genes 
involved in epigenetics and age-related diseases. In chapter 7, we investigated the relation of the 
CREB gene, a histone acetyltransferase (HAT) involved in epigenetic control, with cognitive 
function in old age. Chapter 8 describes a study investigating the relation between the PCAF gene, a 
transcriptional co-activator with intrinsic HAT-activity, and cardiovascular outcomes in three 
different study populations, the PROSPER study, the WOSCOPS study and the GENDER study.  
 
Third, we introduce an innovative approach to investigate the relation between a phenotype and 
outcome independent of confounding and reverse causality by using genetic variation, which is 
called Mendelian randomization. In chapter 9 we investigated whether low cholesterol is a risk 
factor for cancer by using the ApoE genotype, a typical example of a Mendelian randomization 
study. Finally, the main conclusions are summarized and discussed in chapter 10.   
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Abstract 
Inflammation plays a prominent role in the development of atherosclerosis, which is the most 
important risk factor for vascular events. Lymphotoxin alpha (LTA) is a pro-inflammatory 
cytokine and is found to be expressed in atherosclerotic lesions. We investigated the 
association between the C804A polymorphism within the LTA gene and coronary and 
cerebrovascular events in 5804 participants of the PROspective Study of Pravastatin in the 
Elderly at Risk (PROSPER). The primary endpoint was the combined endpoint of death from 
coronary heart disease, non-fatal myocardial infarction, and clinical stroke. Secondary 
endpoints were the coronary and cerebrovascular components separately. All associations 
were assessed with a Cox-proportional hazards model adjusted for sex, age, pravastatin use, 
and country. Our overall analysis showed a significant association between the C804A 
polymorphism and the primary endpoint (p=0.03). After stratification for gender, this 
association was found only in males. Furthermore, we found that the association between the 
C804A polymorphism and the primary endpoint was mainly attributable to clinical strokes 
(p=0.02). The C804A polymorphism in the LTA gene associates with clinical stroke, especially 
in men. But further research is warranted to confirm our results. 
 
Introduction 
Inflammation plays a prominent role in the development of atherosclerosis, which is the most 
important risk factor for vascular events (1-3). Lymphotoxin-alpha (LTA), also known as tumor 
necrosis factor beta (TNFβ), is a pro-inflammatory cytokine which activates a cytokine cascade by 
inducing interleukin-1 (4;5). LTA is expressed in atherosclerotic lesions and induces the expression 
of a number of molecules involved in atherogenesis (6;7). Moreover, atherosclerotic lesions in LTA 
knock-out mice are significantly smaller compared to LTA wild-type mice (7).  
 
Genetic variation in the LTA gene has been associated with vascular disease, like myocardial 
infarction (MI) and stroke (6;8-12). For example, Laxton et al have reported an association between 
the LTA C804A polymorphism and the severity of atherosclerosis in patients with coronary artery 
 
  
25 Chapter 2 
disease (6). They found that carriers of the 804A variant had a higher risk for severe atherosclerosis. 
Furthermore, they found that only the male carriers had this higher risk.  
 
Based on this evidence we hypothesized that genetic variation in the LTA gene is associated with 
vascular disease, especially in men. We assessed the association between the LTA C804A 
polymorphism and coronary and cerebrovascular events in participants of the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER).  
 
Methods 
A detailed description of the protocol of the PROSPER study has been published elsewhere (13;14). 
Here a short outline is provided. 
 
Participants 
The PROSPER study was a prospective multicenter randomized placebo-controlled trial to assess 
whether treatment with pravastatin diminishes the risk of major vascular events in elderly. Between 
December 1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland 
(Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had 
pre-existing vascular disease or increased risk of such disease because of smoking, hypertension, or 
diabetes. A total number of 5804 subjects were randomly assigned to pravastatin or placebo for an 
average 3.5-year intervention period. The primary endpoint in the study was the combined endpoint 
of death from coronary heart disease (CHD), non-fatal myocardial infarct (MI), and occurrence of 
clinical stroke, either fatal or non-fatal. When death occurred following a non-fatal stroke within a 
period of 28 days, it was regarded as a fatal stroke. Secondary endpoints were the separate coronary 
and cerebrovascular components of the primary endpoint. All endpoints were adjudicated by the 
study endpoint committee. More details about the diagnosis of the cerebrovascular and coronary 
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Genotyping 
The single nucleotide polymorphism (SNP) C804A (rs1041981) in the LTA gene was selected 
based on its allele frequency and available literature. A genome wide scan showed two SNPs within 
the LTA gene that were associated with vascular disease (15). An additional study showed that the 
LTA C804A polymorphism is indeed functional and results in an amino-acid change T26N (8). The 
SNP was genotyped by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) 
mass spectrometry (MS), using the Sequenom MassARRAYtm methodology (Sequenom Inc, San 
Diego, CA, USA). Amplification reactions and parameters were based on the manufacturer's 
instructions. Genotyping of the LTA C804A polymorphism was successful in 5389 participants. 
The results of the remaining patients are missing due to lack of DNA or inconclusive genotyping. 
 
Statistical analysis 
The program Haploview (16) was used to estimate the allele frequency and to test the consistency of 
the genotype frequency at the SNP locus with Hardy-Weinberg equilibrium. Hazard ratios (HR) 
with 95% confidence intervals (CI) were calculated with Cox-proportional hazards model. Subjects 
who withdrew consent or deceased during the study were censored on the date they left the study. 
All analyses were adjusted for sex, age, pravastatin use, and country. All analyses were additionally 
sex-stratified performed. To assess whether the PROSPER study is large enough to gain statistical 
power in a sex-stratified analysis, we performed power calculations (Quanto software, 
http://hydra.usc.edu/gxe). Based on a total number of 124 cases with a fatal or non-fatal stroke in 
males (n=2617), we calculated that with a minor allele frequency (MAF) of 20% in a log-additive 
model, a baseline risk of fatal or non-fatal stroke of 4%, and a gene effect of 1.5, the statistical 
power to detect the association between the polymorphism and fatal or non-fatal stroke is 98% for a 
p-value of 5 x 10-2.  
The SPSS software (version 12.0.1, SPSS Inc, Chicago, Ill) was used for all statistical analyses. P-
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Results 
Genotyping of the LTA C804A polymorphism was successful for 5389 subjects, the results of the 
remaining subjects were missing because of insufficient DNA or incomplete genotyping (success 
rate 93.2%). Table 1 represents the baseline characteristics of all 5389 participants divided over 
categories of the C804A polymorphism. About 50% of the participants were male (N=2617) and the 
mean age of all subjects at study entry was 75.3 years. The mean follow-up time was 3.2 years 
(range 2.8-4.0) for participants who did not die or withdrew consent. There were no differences in 
baseline characteristics between genotype groups.  
 
Table 1: Baseline characteristics of the participants of the Prosper study (N=5389). 
 Lymphotoxin-alpha C804A 
 Wt/Wt (N=2102) Wt/Var (N=2547) Var/Var (N=740) 
Continous variates (mean, SD) 
     Age, (years) 
     Body Mass Index, (kg/m2) 
     Total cholesterol , (mmol/L) 
     LDL cholesterol, (mmol/L) 



















Categorical variates (N, %) 
     Female 
     Current smoker 
     History of diabetes 
     History of hypertension 
     History of angina 
     History of claudication 
     History of myocardial infarction 
     History of vascular disease 
































The major allele frequency of the C804A polymorphism was 63% in all participants. The C804A 
polymorphism showed no significant deviation from Hardy-Weinberg equilibrium (p=0.77). The 
genotype frequencies between the three countries differed significantly (p<0.01, data not shown), 
for Scotland the major allele frequency was 62%, for Ireland 61% and for the Netherlands 66%. 
Therefore all analyses were adjusted for country to control for population stratification. 
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Figure 1 shows the association between the C804A polymorphism and the primary endpoint. In the 
overall analysis a significant relation with the primary endpoint was found (p=0.03). The significant 
association of the overall analysis was mainly due to homozygous carriers of the variant (HR 1.27, 
95%CI 1.03-1.55). Furthermore, after stratification for gender, the relation with the primary 
endpoint was especially present in males (HR 1.36, 95%CI 1.04-1.77) and not in females (HR 1.15, 
95%CI 0.84-1.58), although the interaction term for gender with genotype was not significant 
















Figure 1: Association between the lymphotoxin-alpha C804A genotype and the primary endpoint in the 
participants of the Prosper study (n=5389). 
The primary endpoint included coronary heart disease death, non-fatal myocardial infarct, and fatal or non-
fatal stroke. In the overall group a significant association between the C804A genotype and primary endpoint 
was found (p=0.03), namely because an increased risk for the primary endpoint in males (HR 1.36, 95%CI 
1.04-1.77).  
 
We assessed the association of the C804A variant with the coronary and cerebrovascular endpoints 
separately. The association with the primary endpoint in men was mainly attributable to occurrence 
of clinical strokes and not to coronary events (figure 2). The increased risk for clinical stroke for the 
heterozygous carriers was 1.43 (95%CI 0.95-2.15) and for the homozygous male carries 2.07 
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(95%CI 1.24-3.44) (p-trend=0.02). In women, there was no significant association for clinical 
stroke for both the heterozygous carriers (HR 0.94, 95%CI 0.63-1.41) and the homozygous carries 















Figure 2: Association between the lymphotoxin-alpha C804A genotype and vascular endpoints in male 
participants (N=2617). 
The primary endpoint included coronary heart disease death, non-fatal myocardial infarct, and fatal or non-
fatal stroke. Coronary events are coronary heart disease death and non-fatal myocardial infarct. Clinical stroke 
consists of fatal or non-fatal stroke. The association in males with the primary endpoint is namely due to an 
increased risk of clinical stroke (p=0.02). The increased risk for clinical stroke for the heterozygous carriers 
was 1.43 (95%CI 0.95-2.15) and for the homozygous male carries 2.07 (95%CI 1.24-3.44). 
 
Discussion 
We assessed the association between the C804A polymorphism in the LTA gene and vascular 
events in an elderly population at risk for vascular disease. Our results indicate that carriers of the 
804A allele have an increased risk for the primary study endpoint consisting of coronary events and 
clinical strokes. After stratification for gender, this association was only significant in men. 
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Furthermore, we found that the association between the C804A polymorphism and the primary 
endpoint in males was mainly attributable to incident strokes.  
 
Although we found no statistically significant interaction with gender, the association between the 
C804A polymorphism and clinical strokes was only significant in men. Such a sex-specific effect 
has been reported previously (6). Men who were homozygous for the 804A allele were more likely 
to develop atherosclerosis than homozygous females. This finding is in line with our results and fits 
well within the widely recognized difference in susceptibility and severity of atherosclerosis 
between men and women. Men have a higher predisposition to atherosclerosis compared to females 
(17). Likewise, several other genes, like apolipoprotein E, have been shown to have gender specific 
effects on cardiovascular outcomes (18;19). However, further research is necessary to confirm our 
results.  
 
Three studies have previously investigated the association between the LTA gene and the 
susceptibility for stroke (9;10;12). The study of Hagiwara et al found no higher frequency of the 
LTA C804A polymorphism in stroke patients (12). Um et al found an increase of the homozygous 
252G allele in subjects with cerebral infarction compared to controls (9). Szolnoki et al also found 
that the homozygous LTA allele with the 252G and 804A SNPs is more frequent in stroke patients 
than in controls (10). These studies combined with our findings, indicate that carriers of the variant 
allele are indeed at a higher risk for the development of clinical strokes.  
 
We do not have information about the separate ischemic and hemorrhagic strokes. In our study both 
types of strokes were combined into one clinical endpoint. Because we know from previous studies 
in elderly populations that approximately 80 percent of all strokes is attributable to ischemic events 
(20;21), the association between the C804A polymorphism and clinical stroke is probably driven by 
an association between the polymorphism and ischemic stroke. If there is no association with the 
polymorphism and hemorrhagic stroke, then the association we found is an underestimation of the 
true relative risk for ischemic stroke.  
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The whole LTA gene is in strong linkage disequilibrium, therefore the 252G allele naturally 
coexists with the 804A allele (22). Ozaki et al investigated the functionality of the A252G and 
C804A SNPs in the LTA gene (15).The C804A polymorphism causes an amino-acid change from 
threonine (T) to asparagine (N) at codon 26. They found that the variant protein 26N is associated 
with a two-fold increase in the induction of cell-adhesion molecules in vascular smooth muscle cells 
(15). Adhesion molecules are implicated in cardiovascular disease because elevated levels have 
been observed in atherosclerotic lesions (23;24). This might explain the association of the 
polymorphisms in the LTA gene and the increased risk for incident stroke.  
 
In our study we found no association between the LTA polymorphism and myocardial infarction 
(MI). A genome-wide association study identified two functional polymorphisms in the LTA gene 
associated with MI (A252G and C804A) (8). A case-control association study by Ozaki et al found 
that subjects homozygous for the mutant allele (804AA) had an almost two-fold higher risk for MI 
(15). However, three observational studies did not find any association between the LTA 
polymorphisms and myocardial infarction (22;25;25;26). Moreover, a meta-analysis of six studies 
investigating this association found no significant result (22). The association between the LTA 
gene and incident stroke has not been replicated recently. Further research into this association is 
warranted before we can draw definite conclusions from our results. 
 
That we found an association between the LTA C804A genotype and incident stroke and not with 
coronary events is understandable based on available literature (27). Recently, Vanderlaan et al 
suggested that the variation of lesion development at different vascular beds is sensitive to various 
parameters (28). For example, hypertension is one of the main risk factors for atherosclerosis in the 
carotid arteries and for incident stroke whereas smoking is a stronger risk factor for coronary 
atherosclerosis (27). This indicates that cerebrovascular disease has other risk factors than coronary 
disease, which also suggests a different genetic background. LTA 804AA carriers could therefore 
have an increased risk for incident stroke and not for coronary events.  
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A possible weakness of our study is that we have measured only one SNP in the LTA gene. But 
because the SNPs of the LTA gene are in strong linkage disequilibrium, information of one SNP is 
sufficient for analyses. Moreover, we have an enrichment of the variant allele in our study 
population compared to European populations reported in the NCBI database 
(www.ncbi.nlm.nih.gov). However, this does not affect the internal validity.  
 
The strength of our study is that it is a prospective study which is not affected by population 
stratification (29). Because the genotype frequencies differed in the three countries we performed a 
stratified analysis for each country. This analysis showed consistent but not significant results, 
because of lack of statistical power. Another strength is our population size. We had sufficient cases 
of incident stroke to reach a high power for statistical analyses. Furthermore, all participants were 
recruited if they had pre-existing vascular disease or increased risk of such disease because of 
smoking, hypertension, or diabetes, which makes this study population suitable for investigating 
coronary and cerebrovascular diseases.  
 
In conclusion, we found an association of the C804A polymorphism in the LTA gene with the 
primary endpoint, which seems primarily due to an association in men. After separating the 
coronary and cerebrovascular events, we found that the association with the primary endpoint and 
the C804A variant was mainly attributable to clinical stroke. This study is a further argument that 
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Abstract 
Pro-inflammatory cytokines, like interleukin (IL)-6 and tumor necrosis factor-alpha, are 
implicated in the development of atherosclerosis. The role of anti-inflammatory cytokines, like 
IL-10, is largely unknown. We investigated the association of four single nucleotide 
polymorphisms (SNPs) in the promoter region of the IL-10 gene, (4259AG, -1082GA, -592CA 
and -2849GA), with coronary and cerebrovascular disease in participants of the PROspective 
Study of Pravastatin in the Elderly at Risk (PROSPER) trial. All associations were assessed 
with Cox-proportional hazards models adjusted for sex, age, pravastatin use, and country. 
Haplotype analysis of the four SNPs showed a significant association between haplotype 4 
(containing the -592A variant allele) and risk of coronary events (p=0.019). Moreover, analysis 
of separate SNPs found a significant association between -2849AA carriers with incident 
stroke (HR (95%CI): 1.50 (1.04-2.17), p-value = 0.02). Our study suggests that not only pro-
inflammatory processes contribute to atherosclerosis, but that also anti-inflammatory 
cytokines may play an important role. 
 
Introduction 
Inflammatory stimuli, like the pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis 
factor-alpha (TNFα), are implicated in the development of atherosclerosis (1;2). Besides these pro-
inflammatory cytokines, anti-inflammatory cytokines like IL-10 may also play a role in the 
development of atherosclerosis. In IL-10 knockout mice, the absence of IL-10 leads to a marked 
increase in susceptibility of atherosclerosis (3). Furthermore, after occlusion of the middle cerebral 
artery, brain infarcts in IL-10 knockout mice are 30% larger as in wild-type mice (4). These 
preclinical results indicate a possible role for IL-10 in the atherosclerotic process. However, the 
contribution of IL-10 to the modulation of the atherosclerotic process in humans remains largely to 
be elucidated. 
 
IL-10 production levels are under tight genetic control. An extended twin study found that 
approximately two-thirds of the variance in production level of IL-10 is genetically determined (5). 
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Moreover, we have previously reported that genotypic variation in the IL-10 gene is associated with 
significantly lower IL-10 responsiveness upon stimulation with bacterial lipopolysaccharide 
(LPS)(6). 
 
We performed a genetic association study of four IL-10 promoter SNPs (4259AG, -1082GA, -




Study participants come from the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER) trial. A detailed description of the protocol and results of the study has been published 
elsewhere (7). Here a short outline is provided. 
 
Participants 
PROSPER was a prospective multicenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular events in elderly individuals. 
Between December 1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), 
Ireland (Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited if 
they had pre-existing vascular disease or increased risk of such disease because of smoking, 
hypertension, or diabetes. A total number of 5804 subjects were randomly assigned to pravastatin or 
placebo. The primary endpoint was the combined endpoint of fatal coronary heart disease (CHD), 
non-fatal myocardial infarct (MI), and occurrence of clinical stroke, either fatal or non-fatal. 
Secondary endpoints were the separate coronary and cerebrovascular components of the primary 
endpoint. All endpoints were adjudicated by a study endpoint committee. 
 
Genotyping 
We selected four SNPs in the promoter region of the IL-10 gene, 4259AG (rs3024498), -1082GA 
(rs1800896), -592CA (rs1800872), and -2849GA (rs6703630) based on the frequency of the minor 
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allele and possible functionality. All polymorphisms were genotyped by matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS), using the Sequenom 
MassARRAYtm methodology (Sequenom Inc, San Diego, CA, USA). Amplification reactions and 
parameters were based on the manufacturer's instructions. 
 
Statistical analysis 
The program Haploview (8) was used to estimate allele frequencies, test the consistency of 
genotype frequencies at each SNP locus with Hardy-Weinberg equilibrium, and estimate and plot 
pairwise linkage disequilibrium (LD) between the SNPs examined. Haplotypes and haplotype 
frequencies were calculated using SNPHAP software (http://www-gene.cimr.cam.ac.uk/clayton/ 
software). Haplotypes with a frequency of less than 5 % were combined and included in all 
analyses, without reporting the results. The posterior probabilities of pairs of haplotypes per subject 
as estimated by the SNPHAP were used as weights in all analyses. The haplotype analysis approach 
used in this study assumes an additive effect of the haplotypes, and details of this approach have 
been described elsewhere (9). Hazard ratios with 95% confidence intervals (CI) were calculated 
using a Cox-proportional hazards model. All analyses were adjusted for sex, age, pravastatin use, 
and country. The analyses were performed with STATA statistical software, version 9.0 (StataCorp 
LP, Texas, USA).  
 
Results 
The mean age of the participants was 75.3 years and approximately 50% were female (table 1). 
There were significant differences in minor allele frequencies between the countries (p-value Chi-
square < 0.01, data not shown). The variants 4259G, -1082A and -2849A were more common in the 
Irish subjects compared with the subjects from Scotland and the Netherlands. Therefore, all 
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Table 1: Baseline characteristics of the participants of PROSPER per country. 






Continous variates (mean, SD)    
    Age (years) 75.3 (3.4) 75.5 (3.3) 75.1 (3.3) 
    Body Mass index, (kg/m2) 26.7 (4.2) 27.0 (4.4) 26.7 (3.8) 
    Total cholesterol, (mmol/L) 5.7 (1.0) 5.6 (0.9) 5.8 (0.9) 
    LDL cholesterol, (mmol/L) 3.8 (0.8) 3.7 (0.8) 3.9 (0.8) 
    HDL cholesterol, (mmol/L) 1.3 (0.4) 1.3 (0.4) 1.3 (0.3) 
Categorical variates (n, %)    
    Female 1283 (51) 1197 (55) 520 (47) 
    Current smoker 708 (28) 583 (27) 267 (24) 
    History of diabetes 213 (9) 225 (10) 185 (17) 
    History of hypertension 1446 (57) 1441 (66) 705 (64) 
    History of angina 811 (32) 523 (24) 225 (21) 
    History of claudication 229 (9) 114 (5) 47 (4) 
    History of myocardial infarction 379 (15) 258 (12) 139 (13) 
    History of vascular disease 1239 (49) 849 (39) 477 (43) 
    History of stroke or TIA 265 (11) 222 (10) 162 (15) 
Genotype, minor allele frequency (%)    
     IL-10 4259AG  30 33 28 
     IL-10 -1082GA 51 55 50 
     IL-10 -592CA 21 20 21 
     IL-10 -2849GA 30 33 29 
 
Genotyping of the four IL-10 polymorphisms was complete for 5786 subjects. All four SNPs were 
in Hardy-Weinberg equilibrium (all p>0.05). The four SNPs were in strong linkage disequilibrium 
(LD) and occurred together in one haploblock (figure 1). Six haplotypes were found in our study 
population (figure 1B). The four haplotypes with a frequency above 5% were included in analyses. 
We used haplotype2, with no variants present, as reference haplotype. Haplotype1, the most 
frequent, had three variant alleles, 4259G, -1082A and -2849A. Haplotype3 carried the -1082A 
















Figure 1: Haplotype information.  
Figure A shows the linkage disequilibrium (LD) between the single nucleotide polymorphisms (SNPs) 
examined. All SNPs are in LD and occur together in one haploblock. Figure B shows the haplotype 
frequencies. Only the first four haplotypes (frequency> 5%) were included in the analyses. 
 
Haplotype1 was associated with an increased risk for the primary endpoint compared to haplotype2 
(HR (95%CI) 1.14 (1.01-1.29), p= 0.035) (table 2). Carriers of haplotype4, with the -592A variant 
allele, also had a significantly increased risk for the primary endpoint (HR (95%CI) 1.19 (1.04-
1.36), p=0.012). To determine whether the significant haplotype associations with the primary 
endpoint were attributable to coronary events, strokes, or both, we subdivided the primary endpoint 
into coronary events and strokes. The significant association with haplotype4 was due to a 
significant relation with coronary events (HR (95%CI) 1.21 (1.03-1.41), p=0.019). The significant 
association with haplotype1 was not clearly due to coronary events or strokes (HR (95%CI) 1.13 
(0.98-1.30), p=0.082 and HR (95%CI) 1.22 (0.96-1.54), p=0.097 respectively). 
 
Therefore, we performed a single SNP analysis with the three SNPs present in haplotype1, 4259AG, 
-1082GA and -2849GA, to assess the association with coronary events or strokes. No consistent 

























H1 2 1 2 2 0.304 
H2 1 1 1 1 0.269 
H3 1 1 2 1 0.209 
H4 1 2 1 1 0.207 
H5 1 1 2 2 0.009 
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IL-10 -2849AA genotype showed an increased risk of strokes (HR (95%CI): 1.50 (1.04-2.17), p-
value = 0.02) (table 3). In each country a comparable trend was observed. 
 
Table 2: Haplotype analysis with various endpoints in the overall group (n=5786)  




 Haplotype 3 
(1.1.2.1) 
 Haplotype 4  
(1.2.1.1) 
 
 HR (95%CI) HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value 
Primary     
   endpoint 
1.0 (ref) 1.14 
 (1.01-1.29) 
0.035 1.14  
(0.99-1.30) 




   events 
1.0 (ref) 1.13  
(0.98-1.30) 
0.082 1.10  
(0.94-1.29) 




   stroke 







Hazard ratios are assessed with Cox-proportional hazards model adjusted for sex, age, treatment, and country. 
The primary endpoint included coronary heart disease death, non-fatal myocardial infarct, and fatal/non-fatal 
stroke 
 
Table 3: Association between IL-10 -2849GA genotype and stroke in separate countries (n=5786) 









HR 2 vs 1 
(95% CI) 




































This study investigates the association between functional polymorphisms in the promoter region of 
the IL-10 gene with coronary and cerebrovascular events. The haplotype analysis showed an 
association of two haplotypes with the primary endpoint. When we looked at this association in 
more detail haplotype 4, with the -592A variant, was associated primarily with coronary events. The 
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Production of IL-10 is under tight genetic control, with heritability estimates between 50-70% (10). 
Part of this genetic variation comes from polymorphisms in its own promoter sequence (11). We 
have previously reported that carriers of the IL-10 -2849AA genotype have significantly lower IL-
10 responsiveness upon stimulation with bacterial lipopolysaccharide (LPS)(6). Although it is 
unknown whether the -592GA SNP is functional by itself or that it is in linkage disequilibrium with 
another variant, the -592A variant has been associated with low IL-10 production rates (12). 
 
We found that the -592GA polymorphism in the promoter region of the IL-10 gene was associated 
with coronary events. In IL-10 knock-out mice the absence of IL-10 leads to an increased 
susceptibility of atherosclerosis (3). Furthermore, a study with an overexpressing transgenic mice 
model and IL-10 null mice showed a marked difference in lesion size between the groups (13). IL-
10 transgenic mice displayed significantly less atherosclerotic lesion formation compared to wild-
type whereas IL-10 null mice had increased lesion formation (13). Moreover, in patients with acute 
coronary syndromes it was demonstrated that elevated IL-10 serum levels are associated with a 
significantly improved outcome (14). 
 
We also showed that the -2849AA genotype was associated with an increased risk of incident 
stroke. The role of IL-10 in ischaemic brain damage has been evaluated before. Brain infarcts 
produced by occlusion of the middle cerebral artery were 30% larger in IL-10 knockout mice as 
compared with wild-type mice (4). Furthermore, exogenous administration of IL-10 induces 
neuroprotection in rat models of cerebral focal ischaemia (15). Moreover, we have earlier 
demonstrated that elderly subjects with low IL-10 production capacity have an increased risk of 
incident stroke (16). 
 
The reported associations are relatively small. However, due to our large study population they are 
significant and consistent. The strength of our study is that we could replicate the increased risk for 
strokes for -2849AA carriers in three separate study populations. Because we randomized 
participants from three countries, each study group could be used separately. Although the separate 
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associations were not significant due to small numbers, similar trends were observed. Another 
strength of our study is that all subjects were recruited if they had pre-existing vascular disease or 
increased risk of such disease because of smoking, hypertension, or diabetes, therefore genetic 
markers of coronary and cerebrovascular events may be identified easily.   
 
In conclusion, genetic variation in the promoter region of the IL-10 gene is associated with vascular 
events. This provides evidence that not only pro-inflammatory processes contribute to 
atherosclerosis but that also anti-inflammatory cytokines are implicated. These findings support the 
hypothesis that genetic programming of the inflammatory response may be relevant to the 
pathogenesis of atherosclerosis. If these findings are confirmed and adequately explained on the 
basis of independent studies, screening patients for the IL-10 promoter polymorphisms may 
contribute to a better risk stratification of patients at increased risk for atherosclerosis and may 
improve individual treatment.  
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Abstract 
Inflammation is thought to play an important role in the development of cognitive decline and 
dementia in old age. The interleukin-1 signaling pathway may play a prominent role in this 
process. The gene encoding for interleukin-1β-converting enzyme (ICE) is likely to influence 
IL-1β levels. Inhibition of ICE decreases the age-related increase in IL-1β levels and may 
therefore improve memory function. We assessed whether genetic variation in the ICE gene 
associates with cognitive function in an elderly population. All 5804 participants of the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) were genotyped for the 
10643GC, 9323GA, 8996AG, and 5352GA polymorphisms in the ICE gene. Cross-sectional 
associations between the polymorphisms and cognitive function were assessed with linear 
regression. Longitudinal associations between polymorphisms, haplotypes and cognitive 
function were assessed with linear mixed models. All associations were adjusted for sex, age, 
education, country, treatment with pravastatin, and version of test where appropriate. 
Subjects carrying the variants 10643C and 5352A allele had significantly lower IL-1β 
production levels (p<0.01). Furthermore, we demonstrated that homozygous carriers of the 
10643C and the 5352A allele performed better on all executive function tests at baseline and 
during follow-up compared to homozygous carriers of the wildtype allele (all p<0.02). The 
haplotype with two variants present (10643C and 5352A) was associated with better executive 
function (all p<0.02) compared to the reference haplotype without variants. For memory 
function the same trend was observed, although not significant. Genetic variation in the ICE 
gene is associated with better performance on cognitive function and lower IL-1β production 
levels. This suggests that low levels of IL-1β are protective for memory and learning deficits. 
Inhibition of ICE may therefore be an important therapeutic target for maintaining cognitive 
function in old age. 
 
Introduction 
Inflammation plays an important role in the development of cognitive decline and dementia in old 
age (1). The interleukin-1 signaling pathway is likely to have a prominent role in this process (2-5). 
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For example, in rodents peripheral administration of interleukin-1beta (IL-1β) induces various 
cognitive-behavioral effects (2). Furthermore, expression of IL-1β is increased in patients with 
Alzheimer’s disease (5). One of the possible mechanisms by which IL-1β acts on cognitive function 
is by binding to IL-1 type-1 receptors which are abundantly expressed in the hippocampus (3), the 
area of the brain that has a critical role in memory and learning. 
 
IL-1β production capacity is under tight genetic control. An extended twin study found that over 
80% of the variance in production capacity of IL-1β is explained by genetic factors (6). The gene 
encoding for interleukin-1β-converting enzyme (ICE) is likely to be one of the main genes 
influencing IL-1β. ICE mediates the cleavage of the inactive precursor of IL-1β into the biologically 
active form (7). Inhibition of ICE decreases the age-related increase in IL-1β levels (7). Genetic 
variation in the ICE gene is likely to be functional since patients with the 5352AA genotype in the 
ICE gene have an increased risk of developing restenosis after percutaneous coronary intervention, 
a process where inflammation also plays a key role (8).  
 
Since genetic variation in the gene coding for ICE influences expression and function of IL-1β, we 
assessed the association between four polymorphisms within the ICE gene and cognitive function in 
an elderly population.  
 
Methods 
All data come from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). A 




PROSPER was a prospective multicenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular events in elderly. Between 
December 1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland 
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(Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had 
pre-existing vascular disease or increased risk of such disease because of smoking, hypertension, or 
diabetes. A total number of 5804 subjects were randomly assigned to pravastatin or placebo. A large 




The Mini-Mental State Examination (MMSE) was used to measure global cognitive function. The 
MMSE scores range from zero points (very severe cognitive impairment) to 30 points (optimal 
cognitive function). Participants with poor cognitive function (MMSE< 24) were not eligible for 
inclusion in the PROSPER study. Four neuropsychological performance tests were used to measure 
various cognitive domains. The Stroop-Colour-Word-test for attention and the Letter-Digit Coding 
Test (LDT) for processing speed were used to measure executive functioning. The outcome 
parameter for the Stroop test was the total number of seconds to complete the third Stroop card 
containing 40 items. The outcome variable for the LDT was the total number of correct entries in 60 
seconds. Memory was assessed with the 15-Picture Learning test (PLT) testing immediate and 
delayed recall. The main outcome parameters were the accumulated number of recalled pictures 
over the three learning trials and the number of pictures recalled after 20 minutes. The six 
correlation coefficients between the four neuropsychological performance tests varied between 0.29 
(p<0.001) for the Stroop test and the Picture Learning test delayed and 0.77 (p<0.001) for the 
Picture Learning test immediate and delayed. Reliability and sensitivity of these tests in an elderly 
population have been published elsewhere (11).  
Cognitive function was tested at six different time points during the study, before randomization, at 
baseline, after 9, 18, and 30 months, and at the end of the study. The time point of this last 
measurement was different for the participants (at 36-48 months) therefore we performed the 
analyses with their individually varying time-point but report the results for the mean of these time 
points (at 42 months). The pre-randomized measurement was discarded in the analysis to preclude 
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possible learning effects. Since the MMSE is not suitable for longitudinal research because of 
learning and ceiling effects, MMSE scores are not reported here. 
Compound cognitive test scores were constructed by transforming individual test scores into 
standardized Z-scores (Z-score= (individual score–mean population score)/standard deviation of the 
population score) for global cognitive function, executive function and memory function. Global 
cognitive function was calculated by averaging the Z-scores of the Stroop-Colour-Word-test, the 
Letter-Digit Coding test, and the 15-Picture Learning Test immediate and delayed recall. Executive 
function included the Z-scores of the Stroop-Colour-Word-test and the Letter-Digit Coding test. 




We selected four single nucleotide polymorphisms in the ICE gene, 10643GC (rs554344), 9323GA 
(rs488992), 8996AG (rs1977989), and 5352GA (rs580253) based on its minor allele frequency 
(>5%) and to cover the genomic region of the ICE gene for haplotype analyses. Using the HapMap 
database (http://www.hapmap.org) we identified these SNPs as tagSNPs for the existing haplotypes 
within the gene. All SNPs were genotyped by matrix-assisted laser desorption/ionisation time-of-
flight (MALDI-TOF) mass spectrometry (MS), using the Sequenom MassARRAYtm methodology 
(Sequenom Inc, San Diego, CA, USA). Amplification reactions and parameters were based on the 
manufacturer's instructions. 
 
IL-1β production levels 
Cytokine production levels were measured in a randomly chosen subgroup of 411 participants at 
baseline. Whole blood samples were stimulated with 10 ng/ml of lipopolysaccharide (LPS) to assess 
the innate IL-1β production capacity. Unstimulated baseline samples were obtained to serve as a 
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Statistical analysis 
The program Haploview (12) was used to estimate the allele frequencies, test the consistency of the 
genotype frequencies at each SNP locus with Hardy-Weinberg equilibrium, and estimate and plot 
pairwise linkage disequilibrium (LD) between the SNPs examined. Haplotypes and haplotype 
frequencies were calculated using SNPHAP software (http://www-gene.cimr.cam.ac.uk/clayton/ 
software). We used multiple imputation analysis to deal with incomplete data and to account for 
many haplotype probabilities per subject. This method has been described elsewhere in more detail 
(13). Haplotypes with a frequency of less than 5 % were combined and included in all analyses, 
without reporting the results. The haplotype analysis approach used in this study assumes an 
additive effect of the haplotypes, and details of this approach have been described elsewhere (14). 
Cross-sectional associations between the four ICE polymorphisms and cognitive function were 
assessed with linear regression, adjusted for sex, age, education, country, and version of test where 
appropriate. The associations between the four genotypes, the ICE haplotypes and cognitive 
function during follow-up were assessed with a linear mixed model for repeated measurements 
without an interaction term for time and genotype. The estimate for time represents the cognitive 
decline per year. The results for the genotypes represent the mean difference over time between the 
genotypes. All longitudinal analyses were adjusted for sex, age, education, country, use of 
pravastatin, and version of test where appropriate. The SPSS software (version 12.0.1, SPSS Inc, 
Chicago, Ill) was used for all statistical analyses. P-values lower than 0.05 were considered 
statistically significant.  
 
Results 
Table 1 shows the baseline characteristics of the 5804 participants divided over the three countries. 
The mean age of all subjects at study entry was 75.3 years and about 50% of the participants were 
female. There were significant differences in minor allele frequencies between the countries (p-
value Chi-square < 0.01, data not shown). The variants 10643C and 5352A were more common in 
the Dutch subjects compared with the subjects from Scotland and Ireland. Therefore, all analyses 
were adjusted for country. Mean follow-up of study subjects was 42 months (range 36-48 months). 
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Table 1: Baseline characteristics of the participants of the PROSPER study per country. 
 Scotland 
(N=2520) 
Ireland (N=2184) The Netherlands 
(N=1100) 
Continous variates (mean, SD)    
    Age (years) 75.3 (3.4) 75.5 (3.3) 75.1 (3.3) 
    Body Mass index, (kg/m2) 26.7 (4.2) 27.0 (4.4) 26.7 (3.8) 
    Total cholesterol, (mmol/L) 5.7 (1.0) 5.6 (0.9) 5.8 (0.9) 
    LDL cholesterol, (mmol/L) 3.8 (0.8) 3.7 (0.8) 3.9 (0.8) 
    HDL cholesterol, (mmol/L) 1.3 (0.4) 1.3 (0.4) 1.3 (0.3) 
Categorical variates (n, %)    
    Female 1283 (51) 1197 (55) 520 (47) 
    Current smoker 708 (28) 583 (27) 267 (24) 
    History of diabetes 213 (9) 225 (10) 185 (17) 
    History of hypertension 1446 (57) 1441 (66) 705 (64) 
    History of angina 811 (32) 523 (24) 225 (21) 
    History of claudication 229 (9) 114 (5) 47 (4) 
    History of myocardial infarction 379 (15) 258 (12) 139 (13) 
    History of vascular disease 1239 (49) 849 (39) 477 (43) 
    History of stroke or TIA 265 (11) 222 (10) 162 (15) 
Genotype, minor allele frequency (%)    
     ICE 10643GC 17 15 20 
     ICE 9323GA 10 9 11 
     ICE 8996AG 28 28 25 
     ICE 5352GA 17 15 20 
 
Genotyping of the four ICE polymorphisms was complete for at least 5403 subjects. The results of 
the remaining subjects were missing because of insufficient DNA or incomplete genotyping. All 
four SNPs were in Hardy-Weinberg equilibrium (all p>0.3). The four SNPs were in strong linkage 
disequilibrium (LD) and occurred together in one haploblock (figure 1A). Four haplotypes were 
found in our study population (figure 1B). All haplotypes with a frequency above 5% were included 
in analyses. We used H1111, with no variants present, as reference haplotype. H1121 carried the 
9323G variant, H2212 carried three variant alleles, 10643C, 8996A, and 5352A, and H2112 carried 
















Figure 1: Haplotype information.  
Figure 1A shows the linkage disequilibrium (LD) between the single nucleotide polymorphisms (SNPs) 
examined. All SNPs are in LD and occur together in one haploblock. Figure 1B shows the haplotype 
frequencies. All four haplotypes (frequency> 5%) were included in the analyses. 
 
Table 2: Association between four ICE polymorphisms and IL-1β production levels (n=398). 
  Wt/Wt Wt/Var  Var/Var p-value trend 
ICE 10643GC 
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 P-value for trend was assessed with linear regression. Data is presented as mean (SD) 
 
To determine the functionality of the four polymorphisms in our study sample, we assessed the 
difference in IL-1β production capacity over the three genotypes. Subjects carrying the variant 
10643C and 5352A allele had significantly lower IL-1β production levels compared to carriers of 

























H1111 1 1 1 1  0.555 
H1121 1 1 2 1  0.274 
H2212 2 2 1 2  0.102 
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polymorphism, although a trend was seen that the variant allele had a higher IL-1β production 
capacity compared to the wildtype allele.  
 
Table 3: Cross-sectional association between four ICE polymorphisms and cognition on baseline 
 Wt/Wt Wt/Var Var/Var p-value trend 
ICE 10643GC (N) 
    Attention 
    Processing speed 
    Immediate memory 
    Delayed memory 
    Global cognition 
    Executive function 

































ICE 9323GA (N) 
    Attention 
    Processing speed 
    Immediate memory 
    Delayed memory 
    Global cognition 
    Executive function 

































ICE 8996AG (N) 
    Attention 
    Processing speed 
    Immediate memory 
    Delayed memory 
    Global cognition 
    Executive function 

































ICE 5352GA (N) 
    Attention 
    Processing speed 
    Immediate memory 
    Delayed memory 
    Global cognition          
    Executive function  

































All p-values for trend were assessed with linear regression adjusted for sex, education, age, country, and 
where appropriate test of version use 
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The results of the cross-sectional association between the ICE polymorphisms and cognitive 
function at baseline are presented in table 3. Significant associations were found between the 
10643C variant and all cognitive function tests (all p<0.05), the same results were found for the 
association between the 5352A variant and cognitive function (all p<0.05). For the 9323A allele 
comparable results were found, although the effects with memory function were not so strong. 
Subjects with these variant alleles had a better cognitive performance at baseline compared to the 
wild-type allele. Carriers of the 8996G variant performed worse on the Stroop-colour-word test for 
attention (p=0.004). Excluding subjects with a history of stroke did not materially change our 
results. 
 
Table 4 shows the results of the longitudinal association between the ICE polymorphisms and 
cognitive function. Follow-up was complete for 4283 subjects, loss to follow-up was for most of the 
subjects due to mortality. The term for time was significant for all domains of cognitive function, 
indicating that all domains declined over time. The estimates represent the mean difference over 
time between the genotypes. Carriers of the 10643C and 5352A alleles significantly performed 
better on the global and executive function tests (all p< 0.01). For memory function the same trend 
was seen but not statistically significant. The 9323GA was positively associated with attention and 
executive function (p=0.03) but with the other cognitive performance test no association was found. 
Carriers of the 8996G variant performed worse over time on the test for attention (p=0.023).   
Results remained similar when the analyses were done without adjusting for education (data not 
shown). 
 
To assess whether the association between genotypes and cognition was dependent on development 
of stroke, we investigated the occurrence of clinical strokes during follow-up.  There was an equal 
division of the occurrence of clinical stroke between the genotypes (all p>0.5). The results of the 
longitudinal association between ICE polymorphisms and cognitive function did not materially 
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The results of the longitudinal analysis between the ICE polymorphisms and executive function are 
graphically displayed in figure 2. A dose-dependent association was present for the 10643GC, 
9323GA, and the 5352GA polymorphisms with executive function (all p<0.03). With the 8996AG 

















Figure 2: Representation of the longitudinal association between the four ICE polymorphisms and executive 
function. 
P-values for trend represent the mean difference over time over the three genotypes. Black dots with a straight 
line indicates the homozygous wild-type carriers, the heterozygous carries are indicated by black dots and a 
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In table 5 the results of the association between ICE haplotypes and cognitive function during 
follow-up are shown. H1111 was used as reference. As in the SNP analysis, the term for time was 
significant for all domains of cognitive function, indicating that all domains declined over time. 
H2112 with the variant alleles of 10643C and 5352A was associated with better cognitive 
performance on global cognitive function and executive function compared to the reference 
haplotype (all p<0.02). With memory function no associations were found. There also was a 
significant association between H2212 and attention (p=0.045) and executive function (p=0.028). A 
comparable trend was also seen for the other cognitive domains, but did not reach statistical 
significance. There was no association with H1121 and cognition. Excluding subjects with a history 
of stroke and those who suffered a stroke during follow-up did not materially change our results. 
Again, the results remained similar when the analyses were done without adjusting for education.   
 
Discussion 
In this study we investigated the association between genetic variation in the ICE gene and 
cognitive function. We found that subjects carrying the variants 10643C and 5352A had 
significantly lower IL-1β production levels. Furthermore, we demonstrated that carriers of the 
10643C and the 5352A allele performed better on all executive function tests at baseline and during 
follow-up compared to carriers of the wildtype allele (all p<0.02). The haplotype with these two 
variants present (10643C and 5352A) was also associated with better executive function (all 
p<0.02) compared to the reference haplotype without variant alleles. For memory function the same 
trend was observed, although not significant.  
 
A previous study by Gemma et al demonstrated that inhibition of ICE in rats is associated with 
improved memory (7). They showed that the inhibition of ICE and improved memory coincides 
with a decrease in hippocampal IL-1β levels. In our study we showed that carriers of the 10643C 
and 5352A alleles in the ICE gene have lower IL-1β levels compared to carriers of the wild-type 
allele. This suggests that low levels of IL-1β might be protective for memory and learning deficits. 
IL-1β is a pro-inflammatory cytokine which has a key position in the innate immune and 
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inflammatory response by inducing  a pro-inflammatory response (15). Binding to the IL-1 receptor 
evokes cytokines release of pro-inflammatory cytokines like Tumor Necrosis Factor alpha (TNFα), 
Interleukin-6 (IL-6) and Interferon gamma (IFNγ) (figure 2). It was originally described as a 
mediator in the periphery, however, IL-1β has also been reported to be synthesized in the brain (15). 
In addition, IL-1 receptors have been detected in different regions of the central nervous system 













Figure 3: The interleukin-1β converting enzyme (ICE) pathway. 
Pro-IL-1β is cleaved by interleukin-1β converting enzyme into mature IL-1β. The active form of IL-1β binds 
to the IL-1 receptor. This evokes a cytokine release of various pro-inflammatory cytokines like Tumor 
Necrosis Factor alpha (TNFα), Interleukin-6 (IL-6) and Interferon gamma (IFNγ). 
 
The hypothesis that IL-1β associates with cognitive function was first proposed by Lynch in 1998 
(17). She suggested that hippocampal concentration of IL-1β increases with age, while the cause of 
this increase remained unclear. In vitro studies have shown that increase in IL-1β in hippocampal 
tissue would increase lipid-peroxidation possibly by stimulating production of reactive oxygen 
species (18). IL-1β is thought to damage the neuronal membrane by lipid-peroxidation and is 
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thereby accompanied by impairment in expression of long-term potentation (16;19), an 
electrophysiological index of synaptic plasticity linked to memory and learning.  
 
Peripheral administration of IL-1β induces diverse cognitive-behavioral effects. Gibertini et al 
demonstrated that IL-1β injections prior to training on the Morris water maze affects the learning 
ability of mice (2). Furthermore, when injecting the same mice afterwards with an anti-IL-1β 
antibody, the learning on the water maze was normalized. Subsequently, several other studies have 
reported that IL-1β administration induces cognitive defects like decreased exploratory behavior 
and decreased spatial learning (20;21). Moreover, increased expression of IL-1β is associated with 
neurodegenerative diseases like Alzheimer’s disease and vascular dementia (5).  
 
At baseline there were more subjects with a history of stroke within the group of homozygous 
carriers of the variant 10643C and 5352A allele compared to the carriers of the wild-type allele 
(data not shown). During follow-up the carriers of the variant 10643C and 5352A alleles did not 
develop more clinical strokes compared to wild-type carriers. This suggests that the unequal 
division of history of stroke at baseline is due to chance. To exclude the possibility that the better 
cognitive performance of subjects with the variants 10643C and 5352A was caused by a difference 
in prevalence and incidence of stroke, we repeated all analyses excluding subjects with a history of 
stroke or an incidence of stroke or TIA in follow-up. When we excluded subjects with clinical 
stroke in the cross-sectional and longitudinal associations, we still found that subjects carrying the 
10643C and 5352A variant alleles had a better cognitive function compared to wild-type carriers. 
Therefore we think that the better cognitive function in subjects with these two variants is not 
caused by clinical strokes. This supports the hypothesis of Lynch et al (17) that IL-1β induces 
cognitive deficits by inflammation and hippocampal damage in stead of atherosclerosis. 
  
By using TagSNPs in this study we can form the four main haplotypes within the ICE gene, and 
because of the strong linkage disequilibrium we know which SNPs are on which haplotype. H2112 
with the two variants 10643C and 5352A has been found to have a beneficial effect on cognitive 
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function, but both variants may not be functional by themselves. The ICE 5352GA polymorphism 
we investigated is located in exon 5 but does not have an amino acid change as a result and the ICE 
10643GC polymorphism is located in the intronic area of the gene.  These variants might be in 
linkage disequilibrium with other polymorphisms in the gene at this haplotype (22). Although the 
functionality of the ICE polymorphisms is not well-known, we here demonstrated that carriers of 
the 10643C and 5352A variant alleles have a significantly lower IL-1β production capacity. 
Together with our finding that carriers of the 10643C and 5352A variants have better cognitive 
function, it is highly suggestive that low IL-1β levels might causally be related to a better cognitive 
function in old age. 
 
We decided to adjust all analyses for education because education might affect the level of 
cognitive function. It might be argued that this is an overadjustment because prior cognitive ability 
might lead to more education. This might be the reason why education is related to later cognitive 
ability. However, we assessed our analyses also without adjustment for education and the results did 
not materially change. 
 
One of the strengths of our study is our population size. We have prospective data of over 5000 
subjects on cognitive function. Also the fact that we have a follow-up of 42 months with little lost to 
follow-up is a strong element of our study. We used the linear mixed models for our statistical 
analyses because this method can handle repeated measurement accurately. Furthermore, our 
population is appropriate to measure cognitive function because only subjects with a MMSE above 
24 points could participate, which makes it a homogenous study group suitable for investigating 
cognitive function. We did not analyze the cognitive decline over time over the genotype groups 
because we did not expect that carriers will have an additional change per year. We expected that 
they have a difference in cognition developed earlier in life and that in this elderly population we 
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Another strength of our study is that all subjects were recruited if they had pre-existing vascular 
disease or increased risk of such disease because of smoking, hypertension, or diabetes. Despite 
these inclusion criteria as well as the selection for subjects with MMSE scores above 24 we do not 
have an enrichment of the variant 10643C and 5352A alleles within our study population compared 
to the general population. Because the recruitment of subjects with pre-existing vascular disease, we 
could exclude subjects with a stroke in history and follow-up to exclude the possibility that the 
effects are attributable to clinical stroke. 
 
In conclusion, we found an association between the ICE polymorphisms and cognitive function. 
Carriers of the variant 10643C and 5352A alleles performed better on all cognitive function tests 
compared to carriers of the wild-type allele, which was independent of clinical strokes. We also 
found that carriers of the variant alleles had significant lower IL-1β levels than homozygous wild-
type carriers. This suggests that low levels of IL-1β are protective for memory and learning deficits. 
Inhibition of ICE will lower IL-1β levels and might thereby improve cognitive function. ICE 
inhibitors might therefore become an important therapeutic tool for subjects with cognitive decline. 
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Abstract 
Inflammation contributes to the development of cognitive decline in old age in a cytokine-
mediated manner. In contrast, circulating markers of inflammation can poorly be associated 
with cognitive impairment. We assessed the association between genetic variation in the 
promoter region of the interleukin-10 (IL-10) gene and cognitive function in the elderly. All 
5804 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) 
were genotyped for the 4259AG, -1082GA, -592CA and -2849GA promoter polymorphisms in 
the IL-10 gene. Four neuropsychological tests were used to measure cognitive function over a 
mean follow-up period of 42 months. All associations were assessed with linear mixed models 
adjusted for sex, age, education, country and pravastatin use. The estimates and p-values for 
the haplotype analysis were assessed with linear mixed models after multiple imputation 
analysis. We demonstrated that -2849A and 4259G variants were associated with worse 
cognitive function (all p<0.05). Similar trends were observed for the -1082A and -592A 
variants. The haplotype with three variants present (4259G, -1082A and -2849A) was 
associated with decreased cognitive function (all p<0.03). Genetic variation in the promoter 
region of the IL-10 gene is associated with decreased cognitive function in the elderly. 
 
Introduction 
Inflammation plays an important role in the development of cognitive decline and dementia in old 
age (1). There is abundant evidence that inflammatory mechanisms contribute to cognitive 
impairment via cytokine-mediated interactions (1). Animal models expressing high levels of pro-
inflammatory cytokines in the brain suffer from neurodegeneration (2). Furthermore, up-regulation 
of pro-inflammatory cytokines in tissue cultures leads to microglial activation and neuronal damage 
(3) and moreover, several markers of inflammation have been found in and around plaques in the 
brain (4). 
 
Various studies have reported only moderate associations between inflammatory markers and 
cognitive decline (5-7). Therefore, systemic markers are unlikely to be useful as risk predictors for 
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cognitive decline (8). On the contrary, genetic variation in inflammatory genes is more likely to be a 
good marker for risk prediction. Based on Mendel’s law, that inheritance of one trait is independent 
of inheritance of other traits, associations between genetic variation and cognitive function are 
assumed to be unconfounded (9). Moreover, uncertainty exists whether levels of cytokines are risk 
factors for cognitive decline or whether they are a consequence of cognitive decline. Functional 
polymorphisms determine the level of cytokine plasma levels, therefore genetic variation can be 
used as useful marker to overcome this problem of reverse causality.   
 
IL-10 production levels are under tight genetic control. An extended twin study found that 
approximately two-thirds of the variance in production level of IL-10 is genetically determined (10). 
Moreover, we have previously reported that genotypic variation in the IL-10 gene is associated with 
significantly lower IL-10 responsiveness upon stimulation with bacterial lipopolysaccharide (LPS) 
(11). Since genetic variation in the promoter region of the IL-10 gene influences the production 
levels of IL-10, we assessed the association between single nucleotide polymorphisms (SNPs) in the 
promoter region of the IL-10 gene and cognitive function in an elderly population.  
 
Methods 
A detailed description of the protocol of the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER) has been published elsewhere (12;13). A short summary is provided here.  
 
Participants 
PROSPER was a prospective multicenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular events in the elderly. Between 
December 1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland 
(Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had 
pre-existing vascular disease or increased risk of such disease because of smoking, hypertension, or 
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The Mini-Mental State Examination (MMSE) was used to measure global cognitive function. 
MMSE scores range from zero points (very severe cognitive impairment) to 30 points (optimal 
cognitive function). Participants with poor cognitive function (MMSE< 24) were not eligible for 
inclusion in the study. Four neuropsychological performance tests were used to measure various 
cognitive domains. The Stroop-Colour-Word-test for attention and the Letter-Digit Coding Test 
(LDT) for processing speed were used to measure executive functioning. The outcome parameter 
for the Stroop test was the total number of seconds to complete the third Stroop card containing 40 
items. The outcome variable for the LDT was the total number of correct entries in 60 seconds. 
Memory was assessed with the 15-Picture Learning test (PLT) testing immediate and delayed recall. 
The main outcome parameters were the accumulated number of recalled pictures over the three 
learning trials and the number of pictures recalled after 20 minutes. Reliability and sensitivity of 
these tests in an elderly population have been published elsewhere (14). Cognitive function was 
tested at six different time points during the study, before randomization, at baseline, after 9, 18, 
and 30 months, and at the end of the study. The time point of this last measurement was different 
for the participants (at 36-48 months) therefore we performed the analyses with their individually 
varying time-point but report the results for the mean of these time points (at 42 months). The pre-
randomized measurement was discarded in the analysis to preclude possible learning effects. Since 
the MMSE is not suitable for longitudinal research because of learning and ceiling effects, MMSE 
scores are not reported here. 
 
Genotyping 
We selected four SNPs in the promoter region of the IL-10 gene, 4259AG (rs3024498), -1082GA 
(rs1800896), -592CA (rs1800872), and -2849GA (rs6703630) based on the frequency of the minor 
allele and possible functionality. All polymorphisms were genotyped by matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS), using the Sequenom 
MassARRAYtm methodology (Sequenom Inc, San Diego, CA, USA). Amplification reactions and 
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The program Haploview (15)was used to estimate the allele frequencies, test the consistency of the 
genotype frequencies at each SNP locus with Hardy-Weinberg equilibrium, and estimate and plot 
pairwise linkage disequilibrium (LD) between the SNPs examined. Haplotypes and haplotype 
frequencies were calculated using SNPHAP software (http://www-gene.cimr.cam.ac.uk/ 
clayton/software). We used multiple imputation analysis to deal with incomplete data and to 
account for many haplotype probabilities per subject. This method has been described elsewhere in 
more detail (16). Haplotypes with a frequency of less than 5 % were combined and included in all 
analyses, without reporting the results. The haplotype analysis approach used in this study assumes 
an additive effect of the haplotypes, and details of this approach have been described elsewhere 
(17). 
The associations between the four IL-10 SNPs, the IL-10 haplotypes and cognitive function  during 
follow-up were assessed with a linear mixed model for repeated measurements. The estimate for 
time represents the cognitive decline per year. The results for the genotypes represent the mean 
difference over time between the genotypes. All longitudinal analyses were adjusted for sex, age, 
education, country, use of pravastatin, and where appropriate, version of test used. All statistical 
analyses were performed with SPSS software (version 12.0.1, SPSS Inc, Chicago, Ill). P-values 
lower than 0.05 were considered statistically significant.  
 
Results 
The mean age of the participants was 75.3 years and approximately 50% were female (table 1). 
There were significant differences in minor allele frequencies between the countries (p-value Chi-
square < 0.01). The variants 4259G, -1082A and -2849A were more common in the Irish subjects 
compared with the subjects from Scotland and the Netherlands. Therefore, all analyses were 
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Continous variates (mean, SD)    
    Age (years) 75.3 (3.4) 75.5 (3.3) 75.1 (3.3) 
    Body Mass index, (kg/m2) 26.7 (4.2) 27.0 (4.4) 26.7 (3.8) 
    Total cholesterol, (mmol/L) 5.7 (1.0) 5.6 (0.9) 5.8 (0.9) 
    LDL cholesterol, (mmol/L) 3.8 (0.8) 3.7 (0.8) 3.9 (0.8) 
    HDL cholesterol, (mmol/L) 1.3 (0.4) 1.3 (0.4) 1.3 (0.3) 
Categorical variates (n, %)    
    Female 1283 (51) 1197 (55) 520 (47) 
    Current smoker 708 (28) 583 (27) 267 (24) 
    History of diabetes 213 (9) 225 (10) 185 (17) 
    History of hypertension 1446 (57) 1441 (66) 705 (64) 
    History of angina 811 (32) 523 (24) 225 (21) 
    History of claudication 229 (9) 114 (5) 47 (4) 
    History of myocardial infarction 379 (15) 258 (12) 139 (13) 
    History of vascular disease 1239 (49) 849 (39) 477 (43) 
    History of stroke or TIA 265 (11) 222 (10) 162 (15) 
Genotype, minor allele frequency (%)    
     IL-10 4259AG  30 33 28 
     IL-10 -1082GA 51 55 50 
     IL-10 -592CA 21 20 21 
     IL-10 -2849GA 30 33 29 
 
Genotyping of the four IL-10 polymorphisms was complete for 5786 subjects. All four SNPs were 
in Hardy-Weinberg equilibrium (all p>0.3). The four SNPs were in strong linkage disequilibrium 
(LD) and occurred together in one haploblock (figure 1A). Six haplotypes were found in our study 
population (figure 1B). The four haplotypes with a frequency above 5% were included in analyses. 
We used H1111, with no variants present, as reference haplotype. H2122, the most frequent 
haplotype, had three variant alleles, 4259G, -1082A and -2849A. H1121 carried the -1082A variant, 

















Figure 1: Haplotype information.  
Figure A shows the linkage disequilibrium (LD) between the single nucleotide polymorphisms (SNPs) 
examined. All SNPs are in LD and occur together in one haploblock. Figure B shows the haplotype 
frequencies. Only the first four haplotypes (frequency> 5%) were included in the analyses. 
 
Table 2 and figure 2 represents the results of the association between the four IL-10 polymorphisms 
and cognitive function during follow-up. The term for time was significant for all domains of 
cognitive function, indicating that all domains declined over time (table 2). Subjects carrying the 
4259G variant had significantly worse cognitive function compared to carriers of the wild-type 
variant (all p<0.05) as depicted in figure 2A in a gene-dose dependent manner. Also carriers of the 
2849A variant performed worse on all cognitive domains compared to carriers of the wild-type 
variant (figure 2B). The same trend was seen with -1082A and -592A carriers but not significant 
compared to wild-type subjects. Excluding subjects with a history of stroke and those who suffered 
a stroke during follow-up did not materially change our results. There was no significant interaction 




























H1 2 1 2 2 0.304 
H2 1 1 1 1 0.269 
H3 1 1 2 1 0.209 
H4 1 2 1 1 0.207 
H5 1 1 2 2 0.009 





























Figure 2: Representation of association between two IL-10 polymorphisms and cognition.  
Figure2A represents the association between the 4259AG polymorphism with cognition and 2B the 
association between the -2849GA polymorphism with cognition. The straight line represents the homozygous 
wild-type carriers, the dotted line with the squares represents the heterozygous carriers, and the dotted line 
with the triangles represents the homozygous variant carriers 
 
In table 3 the results of the association between IL-10 haplotypes and cognitive function during 
follow-up are shown. H1111 was used as reference. As in the SNP analysis, the term for time was 
A: 4259AG B: -2849GA 
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significant for all domains of cognitive function, indicating that all domains declined over time. 
H2122 with the variant alleles of 4259G, -1082A and -2849A was associated with worse cognitive 
function on all cognitive domains compared to the reference haplotype (all p<0.03). There also was 
a significant association between H1211 and attention (p=0.01). A comparable trend was also seen 
for the other cognitive domains, but did not reach statistical significance. There was no association 
with H1121 and cognition. Excluding subjects with a history of stroke and those who suffered a 
stroke during follow-up did not materially change our results. Again, no significant interaction 
between time and haplotypes was found for all cognitive domains (all p>0.05).   
 
Discussion 
Here we found consistent associations between genetic variation in the promoter region of the IL-10 
gene and cognitive function in an elderly population. In the single SNP analysis we found that 
especially the -2849GA and 4259AG polymorphisms were associated with cognitive function over 
the follow-up period. Carriers of these variants performed significantly worse on all cognitive 
domains. For the other two SNPs, -1082GA and -592CA, the same trend was seen, but not 
significant. Also, the haplotype with three variants present (4259G, -1082A and -2849A) was 
associated with a decreased cognitive function on all cognitive domains. Excluding all subjects with 
a history of stroke and those who suffered a stroke during follow-up did not materially change our 
results. 
 
We found four promoter polymorphisms within the IL-10 gene (4259AG, -1082GA, -592CA and -
2849GA) to be associated with cognitive function. The haplotype most prominently associating 
with different cognitive variables (Table 3) is H2122, which is the only haplotype containing the 
minor allele of 4259AG. This allele on itself associated to cognition with the same significance 
(Table 2). It is very likely that our major haplotype association is driven by the 4295AG SNP. 
Various studies have investigated the association between IL-10 promoter polymorphisms and 
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 The majority of the studies found that the prevalences of the variant alleles of the -1082GA and -
592CA polymorphisms were increased in patients with Alzheimer’s disease compared to healthy 
controls (18-20;23). To our knowledge, no previous studies have been performed so far with the 
other two SNPs, 4259AG and -2849GA. Moreover, to our knowledge we are also the first to 
investigate the association between the four promoter polymorphisms and cognitive function. 
 
It has been shown that patients with Alzheimer’s disease have lower IL-10 serum levels compared 
to healthy controls (18;24). Production of IL-10 is under tight genetic control, with heritability 
estimates between 50-70% (10). Part of this genetic variation comes from polymorphisms in its own 
promoter sequence. We have previously reported that carriers of the IL-10 -2849AA genotype have 
significantly lower IL-10 responsiveness upon stimulation with bacterial lipopolysaccharide (LPS) 
(11). Moreover, Koss et al have demonstrated that the variant -1082A allele is associated with a 
decreased IL-10 production (25). Also, the variant 4259G allele is associated with less IL-10 
transcripts compared to the wild-type 4259A allele (26). Therefore, it is likely that subjects with one 
or more of these polymorphisms have lower IL-10 production capacity. 
 
Because these four polymorphisms in the promoter region of the IL-10 gene are all associated with 
a decrease in IL-10 responsiveness, they are a good reflection of the systemic levels of IL-10. In 
observational studies it usually problematic to exclude the possibility of reverse causality, which 
means that lower levels of IL-10 might be a consequence of the disease rather than a risk factor for 
the disease. Therefore genetic variation is a very useful marker to overcome this problem of reverse 
causality. Furthermore, based on Mendel’s law that inheritance of one trait is independent of 
inheritance of other traits (9), we assume that the association between genetic variation in 
inflammatory genes and cognitive function is unconfounded while the moderate associations found 
with systemic cytokine levels and cognitive function are confounded.  
 
We have showed in a previous study that genetic variation in the promoter region of the IL-10 gene 
is associated with an increased risk for incident stroke (27). To exclude the possibility that the 
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decreased cognitive function in subjects with one or more variant alleles in the promoter region of 
the IL-10 gene was caused by a difference in prevalence and incidence of stroke, we repeated all 
analyses excluding subjects with a history of stroke or an incident stroke during follow-up. When 
we excluded subjects with stroke in all associations, we still found that subjects carrying the variant 
alleles had a decreased cognitive function compared to wild-type carriers. Therefore we think that 
genetic variation in the IL-10 gene decreases cognitive function in the elderly without overt 
evidence of a cerebrovascular event. 
 
One of the strengths of our study is our population size. We have prospective data of over 5000 
subjects on cognitive function in three different countries. Another strength of our study is that all 
subjects were recruited if they had pre-existing vascular disease or increased risk of such disease 
because of smoking, hypertension, or diabetes. Therefore we could exclude subjects with a stroke in 
history and follow-up to strengthen the hypothesis that genetic variation in the IL-10 gene decreases 
cognitive function in the elderly independent of stroke. 
 
Furthermore, our population is appropriate to measure cognitive function because only subjects with 
a MMSE above 24 points could participate, which makes it a homogenous study group suitable for 
investigating cognitive function. Also the fact that we have a follow-up of 42 months with little lost 
to follow-up is a strong element of our study. No interaction between the genotypes and time was 
found, but prior to analysis we did not expect to find this interaction. We assumed that carriers of 
the polymorphisms would have developed a difference in cognition already early in life, therefore 
an additional decline in this elderly population was not expected.  
 
In conclusion, genetic variation in the promoter region of the IL-10 gene is associated with 
decreased cognitive function in individuals without overt evidence of a cerebrovascular event. This 
provides evidence that genetic variation in the IL-10 gene is a good marker for risk prediction of 
cognitive function. If these findings are confirmed and adequately explained on the basis of 
independent studies, screening patients for the IL-10 promoter polymorphisms may contribute to a 
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better risk stratification of patients at increased risk for cognitive decline and may improve 
individual treatment.   
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Abstract 
Various lines of evidence suggest that pro-inflammatory factors may play a role in tumor 
growth and metastasis, the leading cause of cancer-related mortality. However, most evidence 
originates from animal models, only few human studies reported an association between pro-
inflammatory cytokines and death from cancer. Here, we investigated the association between 
circulating levels and innate production capacity of pro-inflammatory cytokines and cancer 
incidence and mortality in the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER). Circulating levels of IL-6 and CRP were measured in all 5804 participants. The 
innate production capacity of IL-6, IL1β and TNFα were measured in a random sample of 403 
subjects. We showed that high circulating inflammatory markers were associated with an 
increased risk of cancer incidence and death from cancer during follow-up (all p< 0.05). 
Moreover, high innate pro-inflammatory cytokine production capacity is associated with an 
increased risk of death from cancer (all p<0.04) but not with higher cancer incidence during 
follow-up (all p> 0.6). In conclusion, high innate production capacity of pro-inflammatory 
cytokines is associated with an increased risk of death from cancer probably due to increased 
tumor growth and metastasis. As there was no association between innate production capacity 
and cancer incidence, the association between circulating levels and cancer incidence at least 
partially reflects reversed causality.  
 
Introduction 
Inflammation plays an important role in the development of various age-related diseases like 
atherosclerosis, stroke, cognitive decline, and dementia (4). Various studies support the hypothesis 
that inflammatory stimuli, like the pro-inflammatory cytokines interleukin-6 (IL-6), interleukin-1-
beta (IL-1β), and tumor necrosis factor-alpha (TNFα) are involved in cancer pathogenesis (5-8). 
Moreover, elevated levels of various cytokines, like IL-1, IL-6, TNF, fibroblast growth factor 
(FGF), and transforming growth factor (TGF) have been found in blood, urine, and ascites of cancer 
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Inflammatory responses are thought to be critical in many aspects of promoting the growth and 
spread of cancers. A recent study of Kim et al showed that cell lines of Lewis lung carcinoma had 
an increased production of the pro-inflammatory cytokines IL-6 and TNFα through activation of the 
Toll-like receptor (TLR) family members TLR2 and TLR6 (10). Moreover, pro-inflammatory 
cytokines are also involved in promoting tumor cell adhesion in metastatic sites which then activate 
local normal cells to produce tumor growth factors (9). Distant-site metastases are the leading cause 
of cancer-associated mortality. Furthermore, animal studies have suggested a role for pro-
inflammatory cytokines in the generation of cancer-associated cachexia, which is the most 
important cause of morbidity among cancer patients (6;11-13).  
 
These various lines of evidence suggest that pro-inflammatory factors may play a role in cancer 
metastasis eventually leading to death. However, most evidence originates from animal models, 
only a few human studies have reported an association between pro-inflammatory cytokines and 
death from cancer (14;15). Here, we investigated the association between circulating levels and 
innate production capacity of pro-inflammatory cytokines and cancer incidence and mortality in the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). 
 
Methods 
A detailed description of the protocol of the PROSPER Study has been published elsewhere 
(16;17). A short summary is provided here.  
 
Participants 
PROSPER was a prospective multicenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular events in the elderly. Between 
December 1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland 
(Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had 
pre-existing vascular disease or increased risk of such disease because of smoking, hypertension, or 
diabetes. A total number of 5804 subjects were randomly assigned to pravastatin or placebo. 
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Inflammatory markers 
In all subjects C-Reactive Protein (CRP) was measured on stored (at –80°C) and previously 
unthawed samples by automated particle-enhanced immunoturbidimetric assay (Roche UK, Welwyn 
Garden City, UK). The method has inter- and intra-assay coefficients of variation of <3%. The 
laboratory participates in the United Kingdom national external quality control for high-sensitivity 
CRP. Interleukin-6 was assayed using a high-sensitivity ELISA (R & D Systems, Oxford, UK) with 
inter and intra-assay coefficients of variation of <6%. All samples were processed by technicians 
blinded to the identity of samples.  
Innate cytokine production capacity was measured in the final 30% of the Dutch participants at 
baseline, resulted in a random subsample of 403 subjects. Whole blood samples were stimulated 
with 10 ng/ml of lipopolysaccharide (LPS) to assess the innate production capacity of IL-1β, IL-6, 
and TNFα. Unstimulated baseline samples were obtained to serve as a control for contamination.  
 
Cancer incidence and mortality 
All subjects included into the PROSPER study did not have a history of malignancy within the 5 
years prior to the start of the trial. Tertiary study endpoints of the PROSPER trial included cancer 
incidence and mortality. All study endpoints were adjudicated by a study endpoint committee. We 
extended the follow-up period for the 1100 Dutch participants of the PROSPER study. First, 
incident cancer was requested for the 1100 subjects at the Dutch cancer registry for the period 
December 1997 and May 1999 until September 2005 (censor date was 15 September 2005). For the 
same period the mortality status was checked for the 1100 Dutch participants. From the deceased 
participants the cause of death was obtained from the Dutch Central Bureau of Statistics. Only the 
primary cause of death on the death certificate was taken into account.  
 
Statistical analysis 
The circulating CRP and IL-6 measurements of all subjects and the innate cytokine production 
levels of the 403 participants were dichotomized in two groups based on the median cytokine 
production level. All associations between the two groups of cytokine production levels and cancer 
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incidence or death from cancer were assessed with a Cox-proportional hazard model adjusted for 
sex, age, current smoking, use of pravastatin and country where appropriate. These associations 
were visually depicted with Kaplan-Meier survival curves. The SPSS software (version 16.0.1, 
SPSS Inc, Chicago, Ill) was used for all statistical analyses. P-values lower than 0.05 were 
considered statistically significant.  
 
Results 
Baseline characteristics of the 5804 subjects of the PROSPER study are presented in table 1. The 
mean age of the subjects was 75.3 years and about half of them were female. The baseline 
characteristics of the random sample of the 403 subjects with additionally obtained innate cytokine 
production capacities are also shown in table 1. Both groups were similar in baseline characteristics.  
 
Table 1: Baseline characteristics of the participants of the PROSPER study 
 Total Group 
(N = 5804) 
Random Sample 
 (N = 403) 
Demographics 
    Age 
    Female, N(%) 
    Education ≥ 13 years 
    Current smokers, N(%) 
    Weight 
















    Cancer incidence 







Data is presented as mean (SD) unless otherwise stated.  
* Measured after 3 years of follow-up 
† Measured after 7 years of follow-up 
 
Cancer incidence and mortality was measured for the total group for a mean follow-up period of 3.2 
years, for the random sample we extended the initial follow-up period with 3.5 years to 6.7 years. 
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The percentages of cancer incidence and cancer mortality are therefore higher in the random 
sample.  
 
Table 2: Association between circulating levels of inflammatory markers and cancer risk  
 Inflammatory marker   








   CRP 














   CRP 













Hazard ratios are assessed with the Cox-proportional hazard model adjusted for sex, age, country, current 
smokers, and use of pravastatin. 
 
The association between circulating inflammatory markers and cancer risk is shown in table 2. The 
hazard ratio for cancer incidence for subjects with high levels of CRP was 1.20 (p=0.06) compared 
to subjects with low CRP levels. Moreover, the hazard ratio for cancer incidence for subjects with 
high levels of interleukin-6 was 1.35 (p=0.003) compared to subjects with low IL-6 levels. High 
levels of both inflammatory markers were also significantly associated with an increased risk for 
death from cancer compared to low levels (HR=1.42, p=0.01 and HR=1.55, p=0.003 respectively).  
 
In table 3 the association is shown between the innate production capacity and cancer risk in a 
random sample of 403 subjects. No associations were found for innate cytokine production capacity 
and cancer incidence. However, innate production capacity levels of the pro-inflammatory 
cytokines IL-1β, IL-6, and TNFα were significantly associated with death from cancer (all p-values 
below 0.04). Participants with high production capacity levels of these cytokines had a higher risk 
for death from cancer compared to participants with low cytokine production levels. There was no 
association between high IL-1β and TNFα cytokine production levels and other causes of death, 
whereas high IL-6 production capacity was also associated with an increased risk for all other 
deaths except cancer (HR 1.92, p=0.04).  
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Table 3: Association between innate inflammatory cytokine production capacity and cancer risk 
 Cytokine level   








    IL-1β 
    IL-6 


















    IL-1β 
    IL-6 

















Hazard ratios are assessed with the Cox-proportional hazard model adjusted for sex, age, current smokers, and 
use of pravastatin. 
 
Discussion 
We assessed the association between circulating levels and innate production capacity of pro-
inflammatory cytokines in whole blood samples and cancer incidence and mortality. High levels of 
the circulating inflammatory markers were associated with an increased risk of cancer incidence and 
death from cancer. Furthermore, we showed that high innate pro-inflammatory cytokine production 
capacity was associated with an increased risk of death from cancer during follow-up, while high 
innate production capacity of pro-inflammatory cytokines was not associated with incident cancer.  
 
We found that a high innate pro-inflammatory cytokine production capacity is a risk factor for 
cancer mortality but not for cancer incidence and also not for any other causes of death. This 
indicates that circulating markers of inflammation are increased in cancer patients, probably by 
autocrine production of the cancer cells themselves. There are two ways to explain the association 
between the innate production capacity of IL-1β, IL-6, and TNFα and death from cancer. First, pro-
































Figure 1: Kaplan-Meier curves 
The dotted line indicates high innate cytokine production capacity; the straight line indicates low innate 
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There are some examples of solid tumors proliferating in response to IL-1, IL-2 and IL-6 (9). 
Cytokines are also involved in promoting tumor cell adhesion in metastatic sites and then activate 
local normal cells to produce tumor growth factors (9). Furthermore, TNFα receptors have been 
associated with tumor cells, suggesting that TNFα could play a role in cancer growth (18-20). The 
most convincing evidence comes from the recent study of Kim et al who reported that cell lines of 
Lewis lung carcinoma had an increased production of the pro-inflammatory cytokines IL-6 and 
TNFα through activation of the Toll-like receptor (TLR) family members TLR2 and TLR6 (10). 
Moreover, both TNFα and TLR2 were found to be required for Lewis lung carcinoma metastases in 
mice (10). 
 
Second, animal studies have suggested that pro-inflammatory cytokines may have a role in cancer 
related cachexia, which is an important cause of morbidity and mortality in cancer patients (6;11-
13). In a tumor model used by Strassmann et al it was suggested that IL-1 and IL-6 are involved in 
mediating cachexia (21;22). Administrating IL-6 antibodies in a similar model partially reversed the 
weight loss. Mice with TNFα producing tumors also developed cachexia and administration of TNF 
neutralizing antibodies reversed the weight loss related to cachexia (19).  
 
While we found an association between circulating inflammatory markers and cancer incidence, we 
found no association between innate production capacity and incident cancer. This might indicate 
that the association between circulating inflammatory markers and cancer incidence might be 
disturbed by reverse causality since it has been shown in various studies that tumor cells have 
autocrine production of pro-inflammatory cytokines (9). Although all participants of the PROSPER 
study had to be free of cancer in the 5 years prior to the study, underlying cancer which had not 
been diagnosed yet could have resulted in higher levels of circulating inflammatory markers. 
Alternatively, strong cancer risk factors may have contributed to an altered inflammatory milieu. By 
investigating the association between innate cytokine production capacity and cancer incidence we 
do not have the problem of reverse causality, since innate production capacity reflects the maximum 
response to LPS in an individual independent of cytokine production by tumor cells. Therefore we 
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suggest that in subjects with cancer a strong pro-inflammatory profile is associated with an 
increased risk of dying, but the increased innate production capacity does not lead to an increased 
risk for developing cancer. 
  
A possible limitation to use the PROSPER study cohort for this research question is that subjects 
were selected to have a history of vascular disease or have an increased risk for such a disease, and 
the results can only be extrapolated with this in mind to the general population. One of the strengths 
of our study is our population size. We had prospective data of over 5000 subjects on various 
outcomes in three different countries. Because of the large population size, we had sufficient cases 
of incident cancer to reach a high power for statistical analyses. Furthermore, all subjects were 
included into the study when they did not have a history of malignancy within the 5 years prior to 
the start of the trial. Cancer incidence and mortality were main outcomes of our study and were 
accurately monitored. Also the fact that we had a follow-up of 3.2 years for all subjects with little 
lost to follow-up is a strong element of our study.  
 
In conclusion, high innate production capacity of pro-inflammatory cytokines is associated with an 
increased risk of cancer mortality probably due to increased tumor growth and metastasis. No 
association was found between innate production capacity and cancer incidence, which indicates 
that the association between circulating levels and cancer incidence is probably disturbed by 
reversed causality. Anti-cytokine therapy for the IL-1b, IL-6, and TNFa cytokines might be of 
therapeutic interest for advanced cancer (1;2). Blocking the pro-inflammatory cytokines by anti-
cytokine based therapies might reduce tumor growth and metastasis, the leading cause of cancer-
associated mortality. Moreover it might reverse cachexia-induced weight loss (3). Hence, when 
tumor growth and progression and cancer-related cachexia can be delayed or reversed by 
administering antibodies against pro-inflammatory cytokines, the survival time for cancer patients 





95 Chapter 6 
Acknowledgements 
This work was performed as part of an ongoing collaboration of the PROSPER study group in the 
universities of Leiden, Glasgow and Cork. This work was partly supported by an investigator 
initiated grant from Bristol-Myers Squibb, USA. Prof. Dr. J.W. Jukema is an Established Clinical 
Investigator of the Netherlands Heart Foundation (2001 D 032). Prof. R.G.J. Westendorp is 
supported by an unrestricted grant from the Netherlands Genomics Initiative (NCHA 050-060-810). 
The IL-6 and CRP arrays are funded by the Chest Heart Stroke Associations. 
 
 
96 High innate production capacity of pro-inflammatory cytokines increases risk of death from cancer 
Reference List 
 
 (1)  Yan L, Anderson GM, Dewitte M, Nakada MT. Therapeutic potential of cytokine and 
chemokine antagonists in cancer therapy. Eur J Cancer 2006 Apr;42(6):793-802. 
 (2)  McMillan DC, Leen E, Smith J, Sturgeon C, Preston T, Cooke TG, et al. Effect of extended 
ibuprofen administration on the acute phase protein response in colorectal cancer patients. 
Eur J Surg Oncol 1995 Oct;21(5):531-4. 
 (3)  McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS. A 
prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer 
patients with weight loss. Br J Cancer 1999 Feb;79(3-4):495-500. 
 (4)  Caruso C, Lio D, Cavallone L, Franceschi C. Aging, longevity, inflammation, and cancer. 
Ann N Y Acad Sci 2004 Dec;1028:1-13. 
 (5)  Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: 
how hot is the link? Biochem Pharmacol 2006 Nov 30;72(11):1605-21. 
 (6)  de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during 
cancer development. Nat Rev Cancer 2006 Jan;6(1):24-37. 
 (7)  Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis 
Rev 2006 Sep;25(3):307-13. 
 (8)  Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 
2007 Apr;19(2):209-16. 
 (9)  Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage 2000 
Sep;20(3):214-32. 
 (10)  Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-
produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009 
Jan 1;457(7225):102-6. 
 (11)  Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with 
cancer. Curr Opin Clin Nutr Metab Care 2005 May;8(3):265-9. 
 (12)  Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T. Pancreatic cancer 
as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J 
Surg 1999 Jun;23(6):584-8. 
 (13)  McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology 
of cancer cachexia. JPEN J Parenter Enteral Nutr 1992 Nov;16(6 Suppl):50S-5S. 
 (14)  Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, et al. Acute-phase 
protein response and survival duration of patients with pancreatic cancer. Cancer 1995 Apr 
15;75(8):2077-82. 
 (15)  Heikkila K, Ebrahim S, Lawlor DA. Systematic review of the association between 
circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 2008 May;44(7):937-45. 
 (16)  Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, et al. The design 
of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study 
 
  
97 Chapter 6 
Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999 Nov 
15;84(10):1192-7. 
 (17)  Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin 
in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. 
Lancet 2002 Nov 23;360(9346):1623-30. 
 (18)  Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its 
receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993 
May;91(5):2194-206. 
 (19)  Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. 
Int J Cardiol 2002 Sep;85(1):161-71. 
 (20)  Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R, Mundy GR. Evidence that 
tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, 
hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest 1991 
Mar;87(3):977-85. 
 (21)  Strassmann G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer 
cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its 
relevance to IL-6-mediated cancer cachexia. J Immunol 1992 Jun 1;148(11):3674-8. 
 (22)  Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer 















99 Chapter 7 
Chapter 7 
 
Variation in the CBP gene involved in epigenetic control associates with 
cognitive function.  
 
Stella Trompet, Anton JM de Craen, J Wouter Jukema, Douwe Pons, P Eline Slagboom, Dennis 









100 Variation in the CBP gene involved in epigenetic control associates with cognitive function 
Abstract 
Research into the pathologic mechanisms of neurodegenerative diseases has revealed that 
CREB Binding protein (CBP) plays an important role in cognitive dysfunction. Loss of one 
copy of this gene leads to a syndrome with severe cognitive dysfunction. We investigated the 
association between four common variants in the CBP gene and cognitive function in 5804 
participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). 
Baseline associations between genetic variation and cognitive function were assessed with 
linear regression. Longitudinal associations were assessed with linear mixed models. All 
analyses were adjusted for sex, age, education, country, version of test, and pravastatin use. 
The intron 4CT and intron 3AC polymorphisms in the CBP gene were associated with better 
cognitive performance at baseline and during follow-up. Furthermore, the haplotype with the 
variant alleles of these two polymorphisms also showed a protective effect on cognitive 
function in all cognitive domains (all p<0.03). Genetic variation in the CBP gene is associated 
with better cognitive performance in an elderly population. Future research is necessary to 
investigate the effect of these polymorphisms on the expression of CBP levels and how these 
polymorphisms affect the gene expression mediated by CBP. 
 
Introduction 
Research into the pathologic mechanisms of complex neurodegenerative diseases has revealed that 
Cyclic AMP Response Element Binding (CREB)- binding protein (CBP) plays an important role in 
memory formation and cognitive dysfunction (1-4). CBP and its close relative p300 are vital 
components of the cellular machinery that regulate gene expression. CBP plays a dual role in gene 
expression (5). First, CBP is involved in epigenetic control as a histone acetyltransferase (HAT) by 
facilitating the binding of transcription complexes to DNA. Second, CBP acts as a co-activator 
interacting with CREB and other transcription factors (5). Therefore, alterations in CBP gene 
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One of the neurodegenerative diseases where CBP is found to be important for cognitive 
dysfunction is the Rubinstein-Taybi Syndrome (RTS) (6;7). RTS is an autosomal dominant disorder 
caused by mutations in the CBP gene. The syndrome is characterized by physical abnormalities 
including broad thumbs and toes, short stature, craniofacial anomalies, and mental retardation (8). 
Loss of one functional copy of the CBP gene underlies all abnormalities in RTS patients (6;7). Oike 
et al have developed a CBP+/- mutant mouse model with a truncated CBP protein (9). These mice 
show the same clinical features as RTS patients, including mental retardation. In the same mouse 
model it was shown that these mice had normal short term memory, but seemed to display 
deficiencies in long term memory, object recognition, and contextual memory tasks (9).  
 
Since loss of one copy of the CBP gene results in severe cognitive dysfunction, we hypothesized 
that common genetic variation in the CBP gene might be associated with cognitive function in the 
general population. Therefore we investigated the association between four single nucleotide 
polymorphisms (SNPs) in the CBP gene and cognitive function in the participants of the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). 
 
Methods 
A detailed description of the protocol of the PROSPER study has been published elsewhere (10;11). 
A short summary is provided here.  
 
Participants 
PROSPER was a prospective multicenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular events in the elderly. Between 
December 1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland 
(Cork), and the Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had 
pre-existing vascular disease or increased risk of such disease because of smoking, hypertension, or 
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Cognitive function 
The Mini-Mental State Examination (MMSE) was used to measure global cognitive function. 
MMSE scores range from zero points (very severe cognitive impairment) to 30 points (optimal 
cognitive function). Participants with poor cognitive function (MMSE< 24) were not eligible for 
inclusion in the study. Four neuropsychological performance tests were used to measure various 
cognitive domains. The Stroop-Colour-Word-test for attention and the Letter-Digit Coding Test 
(LDT) for processing speed were used to measure executive functioning. The outcome parameter 
for the Stroop test was the total number of seconds to complete the third Stroop card containing 40 
items. The outcome variable for the LDT was the total number of correct entries in 60 seconds. 
Memory was assessed with the 15-Picture Learning test (PLT) testing immediate and delayed recall. 
The main outcome parameters were the accumulated number of recalled pictures over the three 
learning trials and the number of pictures recalled after 20 minutes. Reliability and sensitivity of 
these tests in an elderly population have been published elsewhere (12). Cognitive function was 
tested at six different time points during the study, before randomization, at baseline, after 9, 18, 
and 30 months, and at the end of the study. The time point of this last measurement was different 
for the participants (at 36-48 months) therefore we performed the analyses with their individually 
varying time-point but report the results for the mean of these time points (at 42 months). The pre-
randomized measurement was discarded in the analysis to preclude possible learning effects. Since 
the MMSE is not suitable for longitudinal research because of learning and ceiling effects, MMSE 
scores are not reported here. 
 
Genotyping 
We selected four SNPs in the CBP gene (CREBBP), intron 10AG (rs130005), intron 4CT 
(rs11076787), intron 3AC (rs1296720), and intron 2CG (rs2239317). These polymorphisms were 
selected from the SNPper database (http://snpper.chip.org) based on the frequency of the minor 
allele (>5%) and to cover the genomic region of the CBP gene for haplotype analyses. All 
polymorphisms were genotyped by matrix-assisted laser desorption/ionisation time-of-flight 
(MALDI-TOF) mass spectrometry (MS), using the Sequenom MassARRAYtm methodology 
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(Sequenom Inc, San Diego, CA, USA). Amplification reactions and parameters were based on the 
manufacturer's instructions. Each 384-wells plate contained at least 4 positive (CEPH DNA) and 4 
negative controls, to check for assay performance and contaminations, respectively. Spectrocaller 
software supplied by the manufacturer was used to automatically call the genotypes. Clusters were 
checked and all doubtful calls were manually evaluated. Ten percent of the genotypes were 
performed in duplicate and the error rate was below 1%.  
 
Statistical analysis 
The program Haploview (13) was used to estimate the allele frequencies, test the consistency of the 
genotype frequencies at each SNP locus with Hardy-Weinberg equilibrium, and estimate and plot 
pairwise linkage disequilibrium (LD) between the SNPs examined. Haplotypes and haplotype 
frequencies were calculated using SNPHAP software (http://www-gene.cimr.cam.ac.uk/clayton/ 
software). We used multiple imputation analysis to deal with incomplete data and to account for 
many haplotype probabilities per subject. This method has been described elsewhere in more detail 
(14;15). Haplotypes with a frequency of less than 5% were combined and included in all analyses, 
without reporting the results. The haplotype analysis approach used in this study assumes an 
additive effect of the haplotypes, and details of this approach have been described elsewhere (16). 
Cross-sectional associations were assessed using linear regression adjusted for sex, age, education, 
country, and where appropriate, version of test used. The associations between the four CBP SNPs 
and cognitive function during follow-up were assessed with a linear mixed model for repeated 
measurements without interaction with time. In the model we used to estimate the effect of the 
genotypes on cognitive function, we incorporated time as a factor and genotype as covariate. The 
estimates for the genotypes represent the mean difference over time between the genotypes. To 
estimate the cognitive decline over time for all participants we incorporated time as a covariate in 
the model. The estimate for time represents the cognitive decline per year. The associations between 
the CBP haplotypes and cognitive function over time were also assessed with linear mixed models. 
All longitudinal analyses were adjusted for sex, age, education, history of diabetes, hypertension, 
vascular disease, myocardial infarction, stroke or TIA, angina, and claudication, country, use of 
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pravastatin, and where appropriate, version of test used. All statistical analyses were performed with 
SPSS software (version 12.0.1, SPSS Inc, Chicago, Ill). In first instance, p-values lower than 0.05 
were considered statistically significant. Secondly, we adjust our analyses for multiple testing with 
the Bonferroni correction, p-values lower than 0.012 (α = 0.05 / 4 tests) were now considered 
statistically significant.  
 
Results 







Continous variates (mean, SD)    
    Age (years) 75.3 (3.4) 75.5 (3.3) 75.1 (3.3) 
    Body Mass index, (kg/m2) 26.7 (4.2) 27.0 (4.4) 26.7 (3.8) 
    Total cholesterol, (mmol/L) 5.7 (1.0) 5.6 (0.9) 5.8 (0.9) 
    LDL cholesterol, (mmol/L) 3.8 (0.8) 3.7 (0.8) 3.9 (0.8) 
    HDL cholesterol, (mmol/L) 1.3 (0.4) 1.3 (0.4) 1.3 (0.3) 
Categorical variates (n, %)    
    Female 1283 (51) 1197 (55) 520 (47) 
    Current smoker 708 (28) 583 (27) 267 (24) 
    History of diabetes 213 (9) 225 (10) 185 (17) 
    History of hypertension 1446 (57) 1441 (66) 705 (64) 
    History of angina 811 (32) 523 (24) 225 (21) 
    History of claudication 229 (9) 114 (5) 47 (4) 
    History of myocardial infarction 379 (15) 258 (12) 139 (13) 
    History of vascular disease 1239 (49) 849 (39) 477 (43) 
    History of stroke or TIA 265 (11) 222 (10) 162 (15) 
Genotype, minor allele frequency (%)    
    Intron 10AG 21 21 23 
    Intron 4CT 20 18 22 
    Intron 3AC 9 10 11 
    Intron 2CG 9 10 11 
 
The mean age of the participants was 75.3 years and approximately 50% were female (table 1). 
Genotyping of the four CBP SNPs was complete for 5653 subjects. The results of the remaining 151 
subjects were missing because of insufficient DNA or incomplete genotyping. All four SNPs were 
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in Hardy-Weinberg equilibrium (all p>0.3). There was a significant difference in minor allele 
frequency between the countries for the polymorphism intron 3AC (p-value Chi-square = 0.02, data 
not shown). The variant allele C was more common in the Dutch subjects when compared with the 
subjects from Scotland and Ireland. Therefore, all analyses were adjusted for country. Mean follow-
up of study subjects was 42 months (range 36-48 months).  
 
The four SNPs were in strong linkage disequilibrium (LD) and occurred together in one haploblock 
(figure 1A). Four haplotypes were found in our study population (figure 1B). The three haplotypes 
with a frequency above 5% were included in analyses. We used H1111, with no variants present, as 
reference haplotype. H1221 had two variant alleles, intron 4T and intron 3C. H2112 carried the 














Figure 1: Haplotype information.  
Figure 1A shows the linkage disequilibrium (LD) between the single nucleotide polymorphisms (SNPs) 
examined. All SNPs are in LD and occur together in one haploblock. Figure 1B shows the haplotype 
frequencies. Only the first three haplotypes (frequency> 5%) were included in the analyses. 
The results of the longitudinal association between the four CBP polymorphisms and cognitive 


































H1111 1 1 1 1  0.677 
H1221 1 2 2 1  0.192 
H2112 2 1 1 2  0.091 




106 Variation in the CBP gene involved in epigenetic control associates with cognitive function 
Table 2: Longitudinal association between four single polymorphisms in the CBP gene and cognitive function. 
 Time  Mean difference over time 
 Est (SE) p-value  Est (SE) p-value 
Intron 10AG 
    Attention 
    Processing speed 
    Immediate memory 
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    Immediate memory 
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All p-values are assessed with linear mixed models adjusted for sex, age, education, history of diabetes, 
hypertension, vascular disease, myocardial infarction, stroke or TIA, angina, and claudication, country, use of 
pravastatin, , and where appropriate, version of test used. 
 
The term for time was significant for all domains of cognitive function, indicating that all domains 
declined over time. No associations were found with the intron 10AG and intron 2CG 
polymorphisms and cognitive function. Subjects carrying the intron 4T variant had significantly 
better cognitive performance compared to carriers of the wild-type variant on memory function and 
processing speed (all p<0.03). For attention a comparable trend was observed. Also carriers of the 
intron 3C variant performed better on all cognitive domains compared to carriers of the wild-type 
variant (all p<0.01 except for attention). No additional cognitive decline was found when we tested 
for the formal interaction between time and genotype. 
 
  
























Figure 2: Representation of the longitudinal association between the two CBP polymorphisms and cognition. 
Figure 2A represents the association between intron 4CT and cognition and figure 2B the association between 
intron 3AC and cognition. In all graphs it is shown that carriers of the variant alleles performed better 



























































































































































































































B: Intron 3AC A: Intron 4CT 
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Figure 2A represents the longitudinal association between the CBP intron 4CT polymorphism and 
different domains of cognitive function. Carriers of the variant allele had better performance 
compared to carriers of the wild-type allele in a gene-dose dependent relationship. The 
heterozygous subjects performed better compared to the homozygous wild-type carriers and the 
homozygous variant carriers performed better than the heterozygous subjects. In figure 2B the 
association between the CBP intron 3AC polymorphism and cognitive function is presented. Again, 
carriers of the variant allele performed better on all cognitive domains compared to wild-type 
carriers in a gene-dose dependent relationship.  
 
In table 3 the results of the longitudinal association between CBP haplotypes and cognitive function 
are shown. H1111 was used as reference. Again, the term for time was significant for all domains of 
cognitive function, indicating that all domains declined over time. H1221 with the variant alleles 
intron 3T and intron 4C was associated with better memory function and processing speed 
compared to reference (all p<0.03). For attention a comparable trend was seen which was not 
significant. After the Bonferroni correction, H1221 was still significantly associated with better 
memory function (all p<0.012). There was no association between H2112 and cognitive function.  
 
Table 3: Results of the longitudinal association between CBP haplotypes and cognitive function 
 Time  H1111  H1221  H2112 
 Est (SE) p-value  Est (SE)  Est (SE) p-value  Est (SE) p-value 
Stroop 0.68 (0.07) <0.001  Ref  -0.92 (0.65) 0.093  0.15 (0.88) 0.492 
LDT -0.36 (0.01) <0.001  Ref  0.37 (0.18) 0.022  -0.03 (0.23) 0.453 
PLTi -0.01 (0.01) 0.016  Ref  0.11 (0.04) 0.002  0.06 (0.05) 0.128 
PLTd -0.06 (0.01) <0.001  Ref  0.15 (0.06) 0.008  0.04 (0.08) 0.734 
All p-values are assessed with linear mixed models after multiple imputations and adjusted for sex, age, 
education, history of diabetes, hypertension, vascular disease, myocardial infarction, stroke or TIA, angina, 
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Discussion 
In this study we investigated the association between genetic variation in the CBP gene and 
cognitive function. We demonstrate that the intron 4CT and intron 3AC polymorphisms are 
associated with better cognitive performance in all cognitive domains during follow-up. 
Furthermore, the haplotype with the variant alleles of these two polymorphisms also shows a strong 
protective effect on cognitive function in all cognitive domains.  
 
Many experimental studies have investigated the role of CBP in memory formation and cognitive 
dysfunction in animals (1-4). CBP+/- mice show the same clinical features as RTS patients, 
including mental retardation (9). In this mouse model the CBP protein was truncated by lacking the 
intrinsic HAT-domain (9). In the same mouse model it was shown that CBP+/- mutant mice had 
normal short-term memory, but deficiencies in long-term memory, object recognition, and 
contextual memory tasks (9). Moreover, three other mouse models with a defect in the CBP 
pathway (defect in CBP activation (17), truncated form of CBP protein (18) and CBP protein 
lacking HAT activity (19) show that CBP truncated mice have defects in learning and memory.  
 
Loss of one functional copy of the CBP gene underlies all abnormalities in Rubinstein-Taybi 
Syndrome patients (6;7). The mutations found in RTS patients vary from large deletions, which can 
remove the entire gene, to point mutations, which can lead to a truncated protein (7). Therefore it is 
likely that polymorphisms in the CBP gene have an effect on cognitive function, but in a relatively 
milder form compared to RTS patients. Phenotypic effects as described in humans and mice models 
have so far been the result of loss of function mutations. Here we may have found a protective 
effect on cognition of a yet unknown functional variation which is likely to be due to a gain of 
function mutation in LD with haplotype H1221. 
 
A possible weakness of our study is that we genotyped only four SNPs within the CBP gene. These 
polymorphisms were selected to cover the whole genomic region of the CBP gene for haplotype 
analyses. Based on HapMap and Haploview data additional SNPs should have been genotyped to 
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capture all common variation in the CBP gene. It could be a major problem for negative studies if 
not all common genetic variation in a gene is captured, however since our study is not negative, this 
is not a major problem. Moreover, when the additional polymorphisms would be genotyped, only 
three out of the possible 20 haplotypes would contain the two associated polymorphisms (intron 
4CT and intron 3AC). To further refine these three haplotypes, two polymorphisms should be 
additionally genotyped. However these polymorphisms have no effect on the functionality of the 
gene since both polymorphisms are in non-coding areas. 
 
We genotyped four intron polymorphisms with the CBP gene, which may not be functional 
themselves, but may be in linkage disequilibrium with other functional unknown polymorphisms in 
the gene. We have shown that the linkage disequilibrium within this gene is high, therefore the 
protective effect on cognitive function we found with the intron polymorphisms indeed may be 
caused by other polymorphisms within the gene. As a result we do not know the effect of the 
polymorphisms on protein expression levels and protein functionality. Future research is required to 
clarify the relation between the polymorphisms and CBP levels as well as the effect of these 
polymorphisms on gene expression mediated by CBP. However, loss of one copy of the CBP gene 
have been proven to lead to phenotypic effects in Rubinstein-Taybi Syndrome, like severe cognitive 
dysfunction (6;7). This shows that large alterations within this gene cause major defects in cognitive 
function. We have shown that also more frequent single nucleotide polymorphisms within this gene 
can lead to changes in cognitive function.  
 
Moreover, this study met the four criteria described by Rosenthal and Schwartz to establish 
medically useful links between genetic variations and disease (20). First, the change in the gene 
must cause a relevant alteration in the function or level of the gene product (which is always a 
protein); this has been shown since loss of one cope of this gene leads to the Rubinstein-Taybi 
Syndrome with severe cognitive dysfunction. Second, the beneficial and harmful phenotypes must 
have apparent clinical differences; we showed that genetic variation within the CREB gene leads to 
better performance on four neuropsychological performance test in a prospective analyses. Third, 
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the hypothesis linking the genotype to disease must be convincing; this criterion has been met since 
it is known that alterations within the gene lead to this syndrome and fourth, the number of cases 
linking a genotype to disease must be sufficient; this study has been performed in a large study 
group of over 5000 subjects. 
 
A major strength of our prospective study is our large cohort size, with data on several measures of 
cognitive function gathered serially in over 5000 subjects in three different countries. Over a 
follow-up period of 42 months, few subjects were lost to follow-up. As all subjects at study entry 
had an MMSE of 24 points or greater, our observations are highly relevant to comparisons of 
cognitive change in older people with good baseline cognitive functional status, enabling 
stratification of the risk of future decline. Moreover, in previous studies it has been shown that from 
70 years onwards there is substantial cognitive decline. All subjects have significantly deteriorated 
in their cognitive function within the three years of follow-up. No interaction between the genotypes 
and time was found, but prior to analysis we did not expect to find this interaction. We assumed that 
life time exposure of the polymorphisms would have developed a difference in cognition already 
earlier in life, therefore an additional decline in this elderly population was not expected.  
 
In conclusion, we have demonstrated an association between two polymorphisms in the CBP gene 
and cognitive function in an elderly population. The variant alleles of the intron 4CT and intron 
3AC polymorphisms were associated with better cognitive performance in all cognitive domains at 
baseline and in follow-up. Furthermore, the haplotype with the variant alleles of these two 
polymorphisms also showed a protective effect on cognitive function in all cognitive domains. 
Future research is warranted to assess the functionality of these polymorphisms on the expression of 
CBP levels and how these polymorphisms affect the gene expression mediated by CBP. If these 
findings are confirmed and adequately explained on the basis of independent studies, screening 
patients for the CBP polymorphisms may contribute to a better risk stratification of patients at risk 
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Abstract 
This study was designed to investigate the influence of genetic variation in the promoter of the 
gene encoding P300/CBP associated factor (PCAF), a lysine acetyltransferase (KAT) on 
coronary heart disease (CHD) mortality. We investigated the association of genetic variation 
in the promoter region of the PCAF-gene on CHD mortality in two statin trials (PROSPER 
and WOSCOPS) available to us and on restenosis risk in a third study of percutaneous 
coronary intervention (GENDER). We combined the results from these cohorts to examine 
overall effects on CHD mortality and on restenosis risk and determined the contribution of 
PCAF in an animal model of reactive stenosis. Compared with the homozygous -2481G allele 
in the PCAF promoter, we observed a significant reduction in CHD mortality risk with the 
homozygous -2481C PCAF promoter allele in PROSPER (risk reduction 22%; 2%-37%) and 
in WOSCOPS (risk reduction 17%; 14%-39%), and of restenosis in GENDER (risk reduction 
20%; 3%-33%). A combined risk reduction for CHD death/ restenosis for the three studies 
was 21% (15%-26%; p= 8.1 x 10-4). Furthermore, this PCAF allele was significantly 
associated with all cause mortality in PROSPER (p=0.001). Functional analysis showed that 
the -2481 G/C polymorphism affected factor binding to this region of the PCAF promoter, 
and modulation of PCAF gene expression was detectable upon cuff-placement in an animal 
model of reactive stenosis. Our observations promote the concept that epigenetic processes are 
under genetic control and that, other than environment, genetic variation in genes encoding 
KATs may also determine susceptibility to CHD outcomes and mortality. 
 
Introduction 
Investigations into the pathogenetic mechanisms of human complex disease, such as cardiovascular 
disease and cancer, may lead to better risk prediction, treatment and new targets for future therapy. 
Cell proliferation regulatory pathways and pro-inflammatory transcription factors, such as NFκB, 
have been associated with progression of these diseases (1). In the past decade, research into 
cardiovascular diseases such as atherosclerosis and restenosis, has been focused on the 
identification of genetic factors that determine disease risk. Several genes involved in inflammation 
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and cell proliferation appeared to be common denominators of these diseases (2-6). It has become 
clear, however, that part of the gene-environmental interactions relevant for complex diseases is 
regulated by epigenetic mechanisms such as histone acetylation and DNA methylation (7). 
Epigenetic processes modulate gene expression patterns without modifying the actual DNA 
sequence and have profound effects on the cellular repertoire of expressed genes (8). Evidence is 
growing that epigenetic mechanisms also regulate the expression of genes in the inflammatory and 
cell proliferation pathways (9,10) and may therefore also play a role in cardiovascular disease (11-
13) and in cancer (14).  
 
A major influence on gene expression is attributed to the counterbalancing action of lysine 
acetyltransferases (KATs) and lysine deacetylases (KDACs) (15). KATs acetylate histones by 
transfer of an acetyl-group to the -portion of lysine residues, which results in an open modification 
of chromatin structure and in accessibility of DNA to transcription factors and recruitment of the 
basal transcription initiation machinery. Conversely, gene repression is mediated via KDACs, which 
remove acetyl groups and counteract the activity of KATs resulting in a closed chromatin structure. 
Thus far, the main focus has been to investigate the environmental influence on epigenetic 
processes. Research in this field has shown that epigenetic differences arise during the lifetime of 
monozygotic twins (8). Furthermore, oxidative stress has been shown to influence the balance 
between KATs and KDACs in favour of KATs, leading to an increase in inflammation (16). 
Notably, genetic variations in the genes encoding KATs and KDACs, which affect the activities of 
the enzymes they encode, have a bearing on the global and gene-specific levels of histone 
acetylation. As such, these genetic variations in the genes encoding KATs and KDACs could also 
be important determinants contributing to susceptibility to major human diseases. 
 
P300/CBP associated factor (PCAF) is a transcriptional co-activator with intrinsic KAT-activity. 
Besides its role in lysine acetylation of histones at the site of  NFκB-regulated genes and the 
resultant inflammatory gene activation (17,18), PCAF is also found to act as a factor 
acetyltransferase (FAT) that acetylates non-histone proteins, including several tumor-suppressor 
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proteins, such as p53 (19,20) and the phosphatase and tensin homolog (PTEN) (21). Because PCAF 
is involved in proliferation and inflammation, common denominators of the major diseases 
determining human mortality, with clear evidence for inflammatory factors predicting incident CVD 
events (22), incident cancers (23) and mortality, we hypothesized that the PCAF-gene could be of 
major importance in the development of cardiovascular disease and cancer, and death from such 
disease.  
 
We investigated the impact of genetic variation in the promoter region of the PCAF-gene on all-
cause mortality and mortality due to coronary heart disease and cancer in the PROSPER-study, a 
randomized controlled trial in which 5804 elderly patients (age 70-82) at risk for vascular disease 
were randomized to pravastatin or placebo (24). In order to validate the observed effects and to be 
able to extrapolate our findings to a younger population, we investigated the PCAF gene in the 
WOSCOPS study, a randomized controlled trial similar to the PROSPER-study, designed to 
determine the effect of pravastatin in middle-aged men with hypercholesterolemia without a history 
of cardiovascular disease. Finally, in order to further test the validity of results in the two statin 
trials, and to get insights in the mode of action, we investigated these variants in another large 
prospective study, the GENDER-study, a prospective follow-up study that included 3104 patients 
undergoing percutaneous coronary intervention (PCI) (25). The primary endpoint in this study was 
clinical restenosis, a process that is known to be mainly determined by inflammation and 
proliferation (4).  
 
Besides the effect of genetic variants on KAT activity of PCAF, which would affect global and 
gene-specific levels of histone acetylation, the total quantity of acetylated histones can also change 
during life as a result of exposure to environmental factors. This is illustrated by studies with 
monozygotic twins showing that older monozygotic twins differ more from each other in histone 
H3- and H4-acetylation than young monozygotic twins (8). Therefore, as a result of genetic variants 
of PCAF that affect KAT activity in addition to exposure to environmental factors, cumulative 
effects on histone acetylation profiles could become more evident with increasing age. Because of 
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this, we investigated in these three large prospective follow-up studies with various age ranges 
whether the effect of the PCAF gene on mortality and vascular events is associated with increasing 
age. 
 
In short, all patients were analyzed for 2 polymorphisms (SNPs) in the promoter region of the 
PCAF-gene. Of these polymorphisms, the -2481G/C SNP was significantly associated with CHD 
mortality risk in both PROSPER and WOSCOPS, and, in addition, with differential risk for 
restenosis in the GENDER study. The -2481G/C SNP in the PCAF promoter affected transcription 
factor binding as was demonstrated in an electrophoretic mobility shift assay (EMSA) analysis. 
Finally, we demonstrate in an animal model for reactive stenosis (26) that PCAF expression is 




Study Design and Follow-up of the PROSPER Study 
The protocol of PROSPER has been described elsewhere (27). PROSPER is a prospective 
multicenter randomized placebo-controlled trial to assess whether treatment with pravastatin 
diminishes the risk of major vascular events in elderly individuals. Between December 1997 and 
May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the 
Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had pre-existing 
vascular disease or increased risk of such disease because of smoking, hypertension, or diabetes. A 
total number of 5804 subjects were randomly assigned to pravastatin or placebo. In this genetic sub-
study, we evaluated the predefined endpoints all-cause mortality and mortality due to vascular 
events and cancer. Mean follow-up was 3.2 years (range 2.8-4.0) and 604 (10.4%) patients died 
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Study Design and Follow-up of the WOSCOPS Study 
The WOSCOPS study (the West of Scotland Coronary Prevention Study), a primary prevention 
trial, included 6595 men who had LDL cholesterol levels between 174 and 232 mg/dL (4.5 and 6.0 
mmol/L), who had no history of myocardial infarction, but were considered to be at enhanced risk 
for developing CHD (28). All participants were randomly assigned to receive 40 mg of pravastatin 
or placebo daily. The present genetic study was performed in a previously described nested case-
control cohort (29). In brief, the prospective nested case-control study included all of the 580 on-
trial CHD events (death from CHD, nonfatal MI, or revascularization procedures) from the 
WOSCOPS cohort as case subjects and 1,160 control subjects matched to case subjects by age and 
smoking. In the present genetic study we used death from coronary heart disease as our primary 
endpoint. 
 
Study Design and Follow-up of the GENDER Study 
The present study sample has been described previously (25). In brief, the GENetic DEterminants of 
Restenosis project (GENDER) was a multicenter follow-up study designed to study the association 
between various gene polymorphisms and clinical restenosis. Patients eligible for inclusion in the 
GENDER-study were treated successfully for stable angina, non-ST-elevation acute coronary 
syndromes or silent ischemia by PCI in four out of 13-referral centers for interventional cardiology 
in the Netherlands. Patients treated for acute ST-elevation myocardial infarction were excluded. 
Experienced operators, using a radial or femoral approach, performed standard angioplasty and stent 
placement. During the study, no drug-eluting stents were used. Follow-up lasted for at least nine 
months, except when a coronary event occurred. Clinical restenosis, defined as TVR, either by PCI 
or coronary artery bypass grafting (CABG), was the primary endpoint. Median follow-up duration 
was 9.6 months (interquartile range 3.9) and 304 (9.8%) patients underwent TVR during follow-up. 
A prespecified subpopulation of 478 patients was scheduled for re-angiography at 6 months, 
according to standard procedures as described previously (30). Identical projections were used 
before, during and 6 months after the PCI for all assessed angiograms. Quantitative Computer 
Analyses (QCA) were independently performed by Heartcore (Leiden, the Netherlands).   
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For all three studies, all endpoints were adjudicated by independent clinical events committees. The 
protocols meet the criteria of the Declaration of Helsinki and were approved by the Medical Ethics 




Blood was collected in EDTA tubes at baseline and genomic DNA was extracted following standard 
procedures. As a first step to investigate this gene, we selected 2 validated polymorphisms in the 
PCAF-promoter. The -4556 C/T (rs2623074) and the -2481 G/C (rs2948080) polymorphisms were 
selected on the basis of their high minor allele frequency (>5%) and measured using the Sequenom 
Massarray genotyping platform. A multiplex assay was designed using Assay designer software 
(Sequenom). As quality controls, 5-10% of the samples were genotyped in duplo. No 
inconsistencies were observed. Cluster plots of the signals from the low and the high mass allele 
were drawn. Two independent researchers carried out scoring. Disagreements or vaguely positioned 
dots produced by Genotyper 4.0 (Sequenom Inc.) were left out of the results. 
 
Gene Expression Micro-array 
Gene expression micro-array data were generated in 50 unrelated nonagenarians from the Leiden 
Longevity Study, 50 of their offspring and 50 controls. The 150 samples that met the RNA quality 
criteria were hybridized on 54k CodeLink Human Whole Genome Bioarrays (GE Healthcare, 
currently of Applied Microarrays). cDNA synthesis, amplification and biotin labeling and 
hybridization onto the microarray were performed according to the manufacturer’s instructions. 
Two probes on the microarray corresponded to the PCAF gene region; GE693780, corresponding to 
Unigene alignment Hs.668165 and GE81332, corresponding to an exon of the PCAF gene. 
 
Cells and Cell Culture 
The cell lines (HeLa, U251, Raji) used in this study were obtained through the ATCC  (Rockville, 
MD, USA) and were cultured in Iscove’s modified Dulbecco’s medium (IMDM; BioWhittaker 
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Europe, Verviers, Belgium) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS; 
Greiner, Alphen a/d Rijn, The Netherlands), 100 IU/ml streptomycin and 100 IU/ml penicillin. For 
interferon-γ (IFN-γ) induction, cells were treated with 500U/ml of IFN- (Boehringer-Ingelheim, 
Alkmaar, The Netherlands) for 4 hours, hereafter nuclear extracts were prepared (see below). 
HUVECs were cultured in Medium 199 with Earl’s salt and L-glutamine (Life Technologies, Breda, 
The Netherlands), supplemented with 20% (v/v) FCS (PAA, Pasching, Austria), 100 IU/ml 
streptomycin and 100 IU/ml penicillin, 10 IU/ml heparine (Leo Pharma, Breda, The Netherlands) 
and 25 mg bovine pituitary extract (BPE; Life Technologies).  
 
Transcription Factor Binding Site Search 
Potential transcription factor binding sites were identified using the TFSEARCH program 
(http://www.cbrc.jp/research/db/TFSEARCH.html), which searches the TRANSFAC database (31). 
Cutoff was set at 75% of the consensus TF binding site. 
 
Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts and EMSAs were performed as described previously (32). In brief, 2 µl of nuclear 
extracts (HeLa, HUVEC, U251, Raji) in binding buffer were incubated for 30 min on ice, with 2 ng 
of a [33P]-labeled dsDNA probe. The probe sequences were similar to either the C or G promoter 
variants of the PCAF-gene (PCAF-C: 5’-GCAATAAGCCTC-CTCAATCCTTTGCCCTTG-
3’;PCAF-G: 5’-GCAATAAGCCTCCTGAATCCTTTGCCC-TTG-3’). Probe sequences for 
transcription factors MZF1 and GATA1-3 were similar to their previously described consensus 
sequence (MZF1 (zinc fingers 1-4): 5’- GATCTAAAAGTGGGGAGAAAA-3’; MZF1(zinc fingers 
5-13): 5’- GATCCGGCTG-GTGAGGGGGAATCG-3’; GATA: 5’- GGACCTTGATCTTATCTT-
3’) (33,34).  
For competition assays, nuclear extracts were incubated with unlabelled oligonucleotides in 100-
fold excess for 30 min on ice, prior to incubation with the labeled probe. In case of IFN-γ treated 
samples, cells were stimulated with IFN-γ (500U/ml; Boehringer-Ingelheim) for 4-hours prior to 
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preparing nuclear extracts. Samples were run on a 6% polyacrylamide gel in 0.25x TBE-buffer. 
Gels were densitometrically analyzed using the ImageJ software (35).  
 
Mouse Model for Reactive Stenosis 
The institutional committee on animal welfare approved all animal experiments. For all experiments 
hyperlipidemic male ApoE*3-Leiden mice (36) were fed a high-cholesterol diet (ArieBlok, 
Woerden, The Netherlands). Blood samples to determine plasma cholesterol were collected at time 
of surgery. After 3 weeks on diet, a non-constrictive polyethylene cuff was placed loosely around 
one femoral artery and mice were sacrificed at several time points after surgery. After sacrifice, at 
t=0 hours (control, no cuff placement), 6 hours, 24 hours, 2 days, 3 days, 7 days and 14 days, both 
femoral arteries were isolated and snap-frozen in liquid nitrogen (n=6 mice for each timepoint).  
 
RNA Isolation and cDNA Synthesis from Femoral Artery Tissue  
Per time point, femoral arteries were pooled to n=4, allowing better isolation of RNA. After RNA 
isolation, cDNA was synthesized and RT-PCR analysis was performed as previously described (37).  
 
PCAF mRNA Quantification 
Expression levels of PCAF were measured by virtue of quantitative RT-PCR using TaqMan® gene 
expression assay (Mm00451387_m1). PCR runs were carried out in the ABI PRISM 7700 sequence 
detection system (Applied Biosystems, Foster City, CA, USA). HPRT was assayed as control gene 
and its cycle threshold (Ct) was substracted from the Ct of the gene of interest, yielding ΔCt. For 
each timepoint, ΔΔCt was determined by substracting the average ΔCt at timepoint 0 hours from the 
ΔCt at each other timepoint. This ΔΔCt was used to calculate the displayed fold increase for each 
gene (38).  
 
Statistical Analysis 
Allele frequencies were determined by gene counting. The Chi-squared test was used to test the 
consistency of the genotype frequencies at the SNP locus with Hardy-Weinberg equilibrium. 
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Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using a Cox-proportional 
hazards model. All analyses were adjusted for sex and age. The analyses with PROSPER data were 
additionally adjusted for pravastatin use and country. In the GENDER-study, polymorphisms were 
included in a multivariable model containing clinical and procedural risk factors for restenosis, such 
as diabetes, smoking, hypertension, stenting, total occlusion and residual stenosis >20%. A 
combined-effect analysis was performed to pool the results of the effect of the -2481G/C 
polymorphism on study endpoints (all-cause mortality, CHD death and clinical restenosis) and 
coronary endpoints (CHD death in two studies and clinical restenosis in the third study) in the three 
separate studies at old age. The random-effects model was used to consider both the between-study 
and within-study variability. The pooled hazard ratio over the genotypes was assessed with ordinary 





Participant characteristics are presented in table 1. Genotyping success rates were higher than 96% 
for all polymorphisms and there were no significant deviations from Hardy-Weinberg equilibrium. 
 
Using a Cox proportional hazards model, which included several clinical variables such as sex, age, 
pravastatin use, and country, we found a significant association of the -2481 G/C promoter 
polymorphism with all-cause mortality in PROSPER. As presented in table 2 and figure 1, 
heterozygotes had a reduced mortality risk by 17% (2% to 30%, p=0.03), whereas individuals 
homozygous for the -2481C allele had a 39% lower mortality (16% to 56%, p=0.003). The effect of 
PCAF is more profound in the association with coronary heart disease (CHD) death (risk reduction 
22% (2% to 37%), p=0.03) compared to the association with cancer mortality (risk reduction 13% 
(9% to 30%), p=0.22). Due to its proximity to the -2481 G/C polymorphism, we also present the 
data of the -4556 C/T polymorphism (table 2). It shows a small and non-significant trend towards a 
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decrease in all-cause mortality. The linkage disequilibrium (LD)-coefficient between these promoter 
polymorphisms was 0.79. 
 







Continuous variates (mean, SD)    
    Age (years) 75.3 (3.3) 56.8 (5.2) 62.1 (10.7) 
    Body mass index, (kg/m2) 26.8 (4.2) 26.0 (3.2) 27.0 (3.9) 
Categorical variates (%)    
    Male sex 48 100 71 
    Current smoker 27  54 25 
    History of diabetes 11 2 15 
    History of hypertension 62 18 41 
    History of myocardial infarction 13 0 40 
    History of stable angina 27 8 67  
Genotype, minor allele frequency (%)    
    PCAF -4556 C/T a 9 9 11 
    PCAF -2481 G/C b 33 33 33 
All data are presented in number (%) unless otherwise stated.  
a In PROSPER, WOSCOPS, and GENDER, measured in 5583, 1090 and 2850, participants, respectively. 
b In PROSPER, WOSCOPS, and GENDER, measured in 5595, 1092, and 2852, participants, respectively. 
 
WOSCOPS study  
To validate the association of the -2481 G/C polymorphism with CHD mortality, and to investigate 
whether its effect is also present in a population largely without vascular disease, we aimed to 
replicate our findings in a previously described 29 nested case-control cohort of the WOSCOPS 
study. Baseline characteristics of the WOSCOPS study are presented in table 1.  
In this case, the -2481 G/C polymorphism was associated with a non-significant trend towards 
protection against death from coronary heart disease (CHD) (risk reduction 17% (-14% to 39%), 
p=0.26) at all ages. Heterozygotes (risk reduction 11% (-39% to 42%), p=0.62) and homozygotes 
(risk reduction 37% (-36% to 71%), p=0.24) had a non-significantly lower mortality risk. Although 
these data did not reach statistical significance, the point estimate for CHD mortality in WOSCOPS 
was similar to that observed in the PROSPER study (figure 1). The -4556 C/T polymorphism was 
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To extent the observed results in the PROSPER study, we tested the relevance of the gene to clinical 
conditions in which cell proliferation and inflammation play a role in a large patient population 
included in the GENDER-study. In this study patients were followed for at least 9 months after a 
PCI to determine absence or presence of clinical restenosis, as defined by the need for target vessel 
revascularization (TVR). We considered TVR a suitable intermediate endpoint as it is a direct 
consequence of mainly proliferative and inflammatory processes.4  
 
In agreement with the results from the PROSPER and WOSCOPS-study, the -4556 C/T 
polymorphism was not associated with the risk for TVR in the GENDER-study, whereas the -2481 
G/C polymorphism showed a significant association with TVR (p-trend = 0.02) (table 3 and figure 
1). Heterozygous patients were at lower risk for TVR (risk reduction 20% (-2% to 38%), p=0.07), 
and patients carrying two -2481C alleles had a greater protection against the development of 
restenosis (risk reduction 36% (0% to 59%), p=0.05). In analogy of the clinical restenosis (TVR) 
results, carriers of the -2481C allele also had less angiographic restenosis in a subpopulation of 478 
patients undergoing angiography six months after the PCI (risk reduction 44% (4% to 67%), 
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Figure 1: Hazard ratios for all-cause mortality in PROSPER, for coronary heart disease death in WOSCOPS, 
and for clinical restenosis in GENDER by PCAF -2481 G/C genotype at all ages.  
The PCAF -2481 G/C polymorphism is associated with mortality in the PROSPER study, with coronary heart 
disease death in the WOSCOPS study, and with clinical restenosis in the GENDER study in all age groups 
 
Combined Effect Analysis 
Hazard ratios were almost remarkably equal in all three studies (figure 1). Therefore and since all 
three studies have comparable endpoints, we conducted a combined effect analysis to show the 
effect of the -2481C on the study endpoints (CHD death in PROSPER and WOSCOPS, and clinical 
restenosis in GENDER) at all ages (figure 2). The pooled hazard ratio for the- 2481C allele was 
0.79 ((95%CI: 0.74-0.85), p =8.1 x 10-4). Heterozygotes had a reduced risk (HR: 0.82, 95%CI: 0.68-
0.98, p=0.03), and this risk was lower in subjects homozygous for the -2481C allele (HR: 0.61 


















Figure 2: Combined effect estimate of the hazard ratios of the PROSPER, WOSCOPS, and GENDER studies 
for the PCAF -2481 G/C polymorphism. 
This figure represents the hazard ratios for the additive model of the PCAF -2481 G/C polymorphism. 
Coronary endpoints consist of CHD death for the PROSPER and WOSCOPS study, and clinical restenosis for 
the GENDER study do in all and repeat. The top panel is the combined effect analysis at all ages, the bottom 
panel in subgroups with age > 58 years. 
 
Examining for an Age Effect 
From the work of Fraga et al. we know that as a result from exposure to environmental factors the 
total quantity of acetylated histones can change during life and that older monozygotic twins differ 
more from each other in total histone H3- and H4-acetylation than young monozygotic twins (8). 
This means that some (cumulative) effects of histone acetylation could become more evident with 
increasing age. In the PROSPER study we could not demonstrate an effect of the -2481C allele with 
increasing age, since everyone participating in this study was between 70-82 years of age. However, 
in both the WOSCOPS and the GENDER studies, with a considerably wider age range, we could 
indeed identify an effect of the -2481C allele with increasing age. In two age strata we investigated 
the effect of the PCAF -2481 G/C promoter polymorphism on CHD death in the WOSCOPS study. 
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Among participants ≥58 years old (median age), we found that the -2481C allele significantly 
reduced the risk of CHD death (risk reduction 39% (3% to 62%), p= 0.035), whereas there was no 
significant effect in the lower age group. We found similar results in the GENDER study. We again 
observed a strong protective effect of the C-allele in old patients (≥58 years, n=1800) (risk reduction 
30% (12% to 45%), p=0.003) whereas there was no significant effect present in young patients (<58 
years, n=1052). 
 
We also conducted a combined effect analysis to show the effect of the -2481C allele at a high age 
only (median age >58). The pooled hazard ratio for the -2481C allele on coronary events (CHD 
death or TVR) in this high age group was 0.72 ((95%CI: 0.61-0.84), p=4.9 x 10-5), which is 
somewhat stronger than the effect at all ages (figure 2).  
 
Gene Expression Microarray 
To find an explanation for the age-related difference in effect of the -2841 genotype we compared 
the gene expression levels of PCAF between nonagenarians from the Leiden Longevity Study and 
middle-aged controls. For the probe corresponding to an exon of the PCAF gene a lower expression 
level was observed in the nonagenarians compared to the middle-aged controls (FC 0.84, p=0.004). 
No differential expression of PCAF was observed for a probe corresponding to an intronic region of 
the PCAF gene (FC 1.01, p-value 0.90), indicating that the observed expression difference with age 
is specific for the PCAF gene and not for an alternative splice variant. 
 
Functional Involvement: The -2481 Region Encompassing the C/G PCAF Variants 
Using the EMSA technique we tested whether the observed polymorphism would lead to 
differential protein binding in vitro. Using nuclear extracts of different cell types, we studied 
complex formation at the -2481 region of PCAF. We could detect constitutive protein binding to 
both PCAF-C and G-variants (figure 3). In both human umbilical vein endothelial cells (HUVECs) 
and U251 cells nuclear factor binding is enhanced by IFN-γ stimulation. Densitometric analysis 
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revealed that the PCAF G-variant exhibits slightly stronger protein binding than the C-variant. The 










Figure 3: Protein binding to the C- and G-variant of the -2481 region.  
EMSA showing binding of protein to the C- and G-variant of the -2481 region using nuclear extracts of 
various cell-lines. EMSA analysis revealed slightly stronger binding of protein to the G-variant of the -2481 
region. Stimulation of HUVECs with interferon-γ increases nuclear factor binding to the labeled probe 
slightly. In IFN-γ stimulated U251 cells the difference between stimulated and unstimulated cells is much 
more pronounced. Numbers indicate the ratios of optical density (G/C). 
 
Using the TFSearch program, we identified possible binding sites for MZF1 and GATA1-3 in the 
PCAF C-variant promoter. However, ds-oligonucleotides representing binding sites for MZF1 and 
GATA1-3 did not compete with factor binding to the PCAF C-promoter variant (data not shown). 
 
PCAF mRNA Expression in a Mouse Model of Reactive Stenosis 
Placement of a small non-constrictive cuff around the femoral artery in hyper-cholesterolemic (13.9 
± 3.6 mmol/L) ApoE3Leiden mice results in induction of neointima formation. In the developing 
neointima a rapid upregulation of the PCAF expression was observed after cuff placement in a time 
dependent manner (figure 4). PCAF expression showed a peak two days after vascular injury (~1.5 

















Figure 4: Expression of PCAF mRNA in a cuff-induced reactive stenosis mouse model.  
The figure shows PCAF differentially expressed upon activation of the vessel wall in a time dependent 
manner, with an expression peak 48 hours after vascular injury. The data is presented as fold increase 
compared to the control arteries, using HPRT as an internal control for cDNA input. 
 
Discussion 
Our data indicate that the -2481C allele in the gene encoding PCAF, a protein which has been 
shown to acetylate histones at the site of NFkB regulated genes and several non-histone proteins, 
such as the p53 tumor-suppressor proteins, is associated with a significant survival advantage in 
three independent studies. We found in the PROSPER-study an advantage in survival mainly due to 
a significant risk reduction in CHD death. In line with this observation we also observed that the -
2481C allele was associated with a lower death by CHD in the WOSCOPS study in an age 
dependent manner. Furthermore, this allele also protects against clinical and angiographic restenosis 
in the GENDER-study. The effects of the -2481C allele on mortality, CHD death and clinical 
restenosis were more profound at older age (>58 years), which was also corroborated in a gene 
expression array where PCAF expression was found to be reduced in nonagenarians compared to 
middle-aged controls. The -2481G/C polymorphism in the PCAF promoter affects transcription 
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factor binding, as was demonstrated by an EMSA band shift analysis. A role for PCAF in vascular 
disease was further confirmed in a mouse model for reactive stenosis, in which modulation of PCAF 
expression was detected during vascular remodeling. 
 
Our observation in the PROSPER-study that this promoter variant associates to lower mortality 
from cardiovascular disease and cancer as well as clinical restenosis after PCI in GENDER, may 
indicate a role of PCAF in inhibiting cell proliferation also in more general terms. PCAF has been 
shown, for example, to activate p53-responsive enhancer elements within the p21waf1 promoter 
(20) and activity of p21waf1 is known to induce cell-cycle arrest in vascular smooth muscle cells 
(39-42). Furthermore, A20, a NFκB-dependent gene that has been shown to inhibit proliferation of 
VSMCs via increased expression of p21waf1, was able to prevent neointima formation after balloon 
angioplasty in a rat model of carotid artery stenosis (43).  
 
Apart from its well-described role in cell-cycle regulation, PCAF is also known to be required to co-
activate p65-dependent transcription and has been shown to directly activate the transcription of 
several NFκB-regulated genes known to be involved in cardiovascular disease (44). Miao et al. has 
shown that PCAF could enhance the p65 mediated increase in TNF-α promoter activity and that 
high glucose increased the recruitment of PCAF to the TNF-α and COX-2 promoters (17). 
Furthermore, they demonstrated concomitant acetylation of specific lysine residues of histone H3 
and H4 at these promoters. Since TNF-α and COX-2 have been implicated in the development of 
atherosclerosis (45,46), and restenosis (30,47), , and also cancer (48,49), our data suggest that 
PCAF may also play a role in the development of these diseases. 
 
Our finding in the WOSCOPS and GENDER-study that the strong protective effect of the -2481C 
allele was more profound in patients older than 58 years old, whereas it seemed not present in 
young patients (<58 years old) is of particular interest. It could reveal the combined effect of a life-
time dysregulation of PCAF expression resulting from the -2481C genetic variant and the 
accumulating effect of exposure to environmental factors which affect histone acetylation profiles 
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during life as observed by Fraga et al (8). In the PROSPER population such an age dependent effect 
was not observed as this trial included only patients >70 years old. As expected, here the effects on 
cardiovascular and cancer mortality associated with the PCAF -2481 G/C polymorphism were 
evident for the entire population. After observing an age-dependent effect in the WOSCOPS and 
GENDER study, we suggest that this polymorphism in PCAF is associated with an altered tendency 
to acetylate histones and non-histone proteins (such as the tumor-suppressor p53 whose function 
relies on acetylation, reviewed in Spange et al.(50)) and may therefore become important especially 
in elderly patients, who may have been under the influence of altered PCAF activity for many years.  
 
Although our findings in the GENDER-study do not directly replicate the effect of the -2481 G/C 
polymorphism on CHD mortality in the elderly, they are of much value as this study has a 
mechanistically linked and better defined concise endpoint. Thus in this way patho-physiologic 
insights would be obtained and not just replication only. Restenosis after a PCI is very well 
investigated and is now known to be mainly the consequence of inflammatory and proliferative 
processes, which is underscored by the fact that stents eluting drugs that suppress these processes 
are highly efficacious in the prevention of restenosis. Therefore, we believe that our finding that the 
-2481C allele protects against restenosis in the GENDER-study does not only confirm its functional 
significance, but also provides mechanistic insights in its beneficial role in survival in the 
PROSPER and WOSCOPS studies. 
 
Although we show the association between this locus involved in epigenetic control and clinical 
conditions in three large follow-up studies with a mechanistically linked endpoint, our studies 
warrant further investigation into the influence of the -2481 G/C polymorphism on the activity of 
the PCAF promoter or expression levels of NFκB-regulated genes. Our data that PCAF expression 
is reduced in nonagenarians when compared to middle-aged controls confirms a role for this gene in 
survival and suggests that the -2481C variant leads to reduced transcription of the PCAF gene. 
Further research has to be performed to test this hypothesis. In a first analysis we were able to 
demonstrate binding of nuclear protein extracts to the specific region flanking the -2481 G/C 
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polymorphism in the PCAF promoter. EMSA analysis showed that the G-variant exhibits a higher 
affinity for nuclear factor binding than the C-variant, albeit a relatively small difference. The 
difference observed, however, might lead to a dramatic different outcome if the effects accumulate 
over years. In initial experiments we were unable to elucidate the nuclear factor binding to the -
2481 region. Thus the protein(s) leading to the different outcome in disease remain(s) to be 
elucidated. It should be noted that IFN-γ stimulation increases nuclear factor binding in HUVECs 
and U251 cells, suggesting a role for IFN-γ induced nuclear factors. To further explore the role of 
this gene in vascular disease, we quantified PCAF-transcripts in the stenotic vessel wall in a mouse 
model of cuff induced reactive stenosis in the femoral artery. During the stenotic process, the PCAF 
gene expression was rapidly upregulated, indicating that PCAF gene expression is activated upon 
vascular injury and suggesting that this transcriptional coactivator is involved in the development of 
reactive stenosis, at least in the early stages.  
 
In conclusion, we showed in three large prospective studies that the -2481C allele in the PCAF 
promoter is associated with a significant survival advantage in elderly patients while also protecting 
against clinical and angiographic restenosis after PCI. Although the exact mechanisms of these 
actions are thus far unknown, we suggest that the effect of this allele on these endpoints may be due 
to the well-known involvement of PCAF in inflammatory and proliferative processes. Our results 
indicate that this locus may be involved in the modulation of cardiovascular event or mortality, 
probably by epigenetic histone modifications, which may be a target for future therapy.  
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Abstract 
Observational studies have shown an association between low plasma cholesterol levels and an 
increased risk of cancer whereas most randomized clinical trials with cholesterol lowering 
medications have not shown this association. The authors assessed the association between 
plasma cholesterol levels and cancer risk, free from confounding and reverse causality, by a 
Mendelian randomization study design using the ApoE genotype. ApoE genotype, plasma 
cholesterol levels, and cancer incidence and mortality were measured during three years in 
2,913 participants in the PROspective Study of Pravastatin in the Elderly at Risk. Subjects 
within the lowest third of plasma cholesterol level at baseline had an increased risk of cancer 
incidence (HR (95% CI) = 1.90 (1.34, 2.70)) and cancer mortality (HR (95% CI) = 2.03 (1.23, 
3.34)) relative to subjects within the highest third of plasma cholesterol. However, carriers of 
the ApoE2 genotype (n=332), who had 9% lower levels of plasma cholesterol than carriers of 
the ApoE4 genotype (n=635), did not have in increased risk of incident cancer incidence (HR 
(95% CI) = 0.86 (0.50, 1.47)) or cancer mortality (HR (95% CI) = 0.70 (0.30, 1.60)) compared 
to ApoE4 carriers. Our findings suggest that low levels of cholesterol are not causally related 
to an increased risk of cancer. 
 
Introduction 
Numerous observational studies have reported an association between low plasma cholesterol levels 
and increased risk of cancer (1-6). This has led to concerns that treatment or lifestyle changes that 
lower cholesterol might increase cancer risk. However, these observed associations between low 
plasma cholesterol and increased risk of cancer might originate from reverse causality or 
confounding. For example, low plasma cholesterol levels might be caused by a hypocholesterolemic 
effect of cancer in preclinical stages of cancer (7). In this case, subjects with cancer have an 
abnormal low cholesterol level because of the cancer and not vice versa (reverse causality). 
Furthermore, confounding factors such as age, smoking, and alcohol use might also explain some of 
the observed associations. Most randomized clinical trials have shown that cholesterol lowering 
medications (statins) have no effect on cancer risk (8-12), although some exceptions have been 
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reported (13;14). However, the length of these trials was limited and the answer to the question 
whether a lifelong low plasma cholesterol level increases cancer risk has remained elusive. 
 
An alternative epidemiological method, Mendelian randomization, overcomes the problem of 
reverse causality and confounding since it is based on Mendel’s law that inheritance of one trait is 
independent of inheritance of other traits (15). This means that the association between a genetically 
determined phenotypic trait and a disease is unlikely to be caused by reverse causality or 
confounding, provided that the presence of the genotype that causes the trait does not influence the 
subject’s lifestyle or environment. This condition will usually be fulfilled as long as subjects are 
unaware of their genotype. 
 
In 1986, one of us (MBK) first suggested to investigate the causality of the relation between plasma 
cholesterol and cancer by investigating the relationship between ApoE genotype and cancer risk 
(16). ApoE is involved in the clearance of lipoproteins from plasma and differences in its aminoacid 
sequence produce differences in plasma cholesterol levels within a population. Three independent 
alleles of the ApoE gene occur frequently. They give rise to the isoforms E2, E3, and E4, with one 
cysteine residue being replaced by arginine from E2 to E3 and another one from E3 to E4. Plasma 
cholesterol levels rise from E2 to E3 to E4. Therefore, if low cholesterol levels promote tumour 
growth, then subjects with the E2/E2 or E2/E3 phenotype should have the highest risk of cancer. 
Our way of analysis (16) constituted the first instance of what would later be named Mendelian 
randomization (17). In the cholesterol and cancer debate it has never been put to the test. We here 
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Methods 
Participants 
Study participants came from the placebo group of the PROspective Study of Pravastatin in the 
Elderly at Risk (PROSPER) trial. A detailed description of the protocol and results of the study 
have been published elsewhere (13;18). Here a short outline is provided. 
 
PROSPER was a multicenter randomized placebo-controlled trial to assess whether treatment with 
pravastatin decreases the risk of major vascular events in elderly individuals. Between December 
1997 and May 1999, we screened and enrolled subjects in Scotland (Glasgow), Ireland (Cork), and 
the Netherlands (Leiden). Men and women aged 70-82 years were recruited if they had pre-existing 
vascular disease or had increased risk of such disease because of smoking, hypertension, or 
diabetes. Subjects with a history of malignancy within 5 years prior to the trial were not eligible to 
participate. A total number of 5804 subjects were randomly assigned to pravastatin (N=2,891) or 
placebo (N=2,913). In our study, all analyses were performed in subjects with placebo allocation 
(N=2,913) so that a possible effect of pravastatin on cancer could not affect our results. The primary 
endpoint was the combined endpoint of fatal coronary heart disease (CHD), non-fatal myocardial 
infarct (MI), and occurrence of clinical stroke, either fatal or non-fatal. Other study endpoints were 
occurrence of transient ischemic attack, disability, cognitive function, and cancer incidence and 
mortality. Information on all deaths were received by post-mortem reports, death certificates, 
hospital records, general practitioners’ records, and/or interviews of family members or witnesses. 
All endpoints were adjudicated by a study endpoint committee. Mean follow-up duration was 3.2 
years (range 2.8-4.0). 
 
Measurements 
Plasma cholesterol levels were measured twice at fasting visits during the placebo run-in phase 
according to the Lipid Research Clinics protocol (19) in a central laboratory which was standardized 
through the Center for Disease Control network. The second measurement during the placebo run-in 
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phase was used as the baseline measurement. During the follow-up of the PROSPER study, lipid 
and lipoprotein measurements were again performed after 3, 6, 12, 24, and 36 months.  
Apolipoprotein E phenotype was determined on plasma samples by western blotting following the 
method of Havekes et al.(20). Subjects were classified according to the presence of the E2, E3, or 
E4 bands on gel blots. The gel phenotyping method shows very high concordance (>95%) with 
genotype testing by allele specific oligonucleotide assay, therefore we consider this measurement as 
a measurement of the ApoE genotype (21).  
 
Statistical analysis 
All statistical analyses were performed in subjects with placebo allocation so that a possible effect 
of pravastatin on cancer could not affect our results. For the association with ApoE genotype, 
participants were divided into three categories, E2+ (genotypes E2/2, E2/3), E3/3 (the most frequent 
genotype) and E4+ (genotypes E3/4, and E4/4). Subjects with the ApoE2/4 (n=59) were excluded 
from all analyses. The plasma cholesterol levels measured at baseline were divided in three equal 
strata representing low (<5.22 mmol/L), intermediate (5.22-6.02 mmol/L) and high plasma 
cholesterol levels (>6.02 mmol/L). The association between ApoE genotype and plasma cholesterol 
level was assessed by linear regression. The cross-sectional associations between ApoE genotypes, 
plasma cholesterol levels, and potential confounders were assessed using the linear by linear 
association test for categorical variables and by linear regression for continuous variables. Hazard 
ratios (HR) with 95% confidence intervals (CI) for cancer incidence and cancer mortality were 
calculated using Cox-proportional hazards models. Subjects who died of other causes of death than 
cancer, subjects who withdrew consent, and subjects who were lost to follow-up were censored at 
the date of death or at the last date of follow-up. In all adjusted analyses we corrected for the 
potential confounders of gender, age, current smoking, alcohol use, history of hypertension, 
diabetes, and myocardial infarction. All analyses were performed with SPSS statistical software 
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Results 
The mean age of the participants was 75.3 years and approximately 50% were female (Table 1). 
Mean follow-up of study subjects was 3.2 years (range 2.8-4.0) for participants who did not die or 
withdraw consent. Of the 2913 subjects allocated to placebo, apolipoprotein E phenotyping was 
available for 2794 (95.9%). The category E2+ consisted of 332 (12%) subjects, E3/E3 of 1768 
(63%) subjects, and E4+ of 694 (25%) subjects. Translated into genotypes, the frequencies were in 
Hardy-Weinberg equilibrium. The genotype frequencies between the three countries were not 
significantly different (P=0.15). 
 
Table 1: Baseline Characteristics of the Participants in the Placebo Arm of the PROSPER Study 
 All participants 
(n=2,913) 
Continuous variates (mean, SD)  
    Age (years) 75.3 (3.4) 
    Body Mass index, (kg/m2) 26.8 (4.3) 
    Total cholesterol, (mmol/L) 5.7 (0.9) 
    LDL cholesterol, (mmol/L) 3.8 (0.8) 
    HDL cholesterol, (mmol/L) 1.3 (0.4) 
Categorical variates (n, %)  
    Female 1,505 (52) 
    Current smoker 805 (28) 
    Diabetes 320 (11) 
    Hypertension 1,793 (62) 
ApoE genotype (n, %)*  
    E2+     
    E3/E3  




* ApoE genotype was measured in 2,735 participants 
 
The association between the ApoE genotypes and plasma lipoprotein levels is depicted in Figure 1. 
As expected, ApoE2/E2 carriers had lowest plasma cholesterol levels (mean 5.26 (SE 0.25)), 
ApoE3/3 subjects had intermediate plasma cholesterol levels (mean 5.66 (SE 0.02)) and subjects 
with the ApoE4/E4 genotype had the highest plasma cholesterol levels (mean 5.97 (SE 0.12)). The 
p-value for trend over the five categories was statistically significant (P<0.01).  
 
  















Figure 1: Association between ApoE genotype and plasma cholesterol levels.  
Plasma cholesterol levels (mmol/L) are presented in mean (se). 
 
We divided participants in three equal strata representing low, intermediate and high plasma 
cholesterol levels, and compared various characteristics between the subjects within these three 
groups. Gender, alcohol use, current smoking, history of diabetes, history of myocardial infarction 
and history of hypertension were all significantly different over strata of cholesterol (Table 2, all P= 
or <0.01). As expected, when we divided the subjects in the three ApoE genotype groups, 
cholesterol level significantly increased over strata of ApoE genotype (P<0.01). We found the same 
trend for LDL cholesterol levels with ApoE2 carriers having the lowest LDL level and ApoE4 
carriers the highest levels (P<0.01). For HDL cholesterol levels the trend was reversed, ApoE2+ 
carriers had the highest levels and ApoE4+ the lowest HDL levels (P=0.01). However, no other 
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During follow-up there were 199 subjects who developed cancer and 91 subjects who died of it. The 
results of the association between plasma cholesterol levels and ApoE genotype on the one hand 
and cancer incidence and cancer death on the other hand are shown in Table 3. The group with low 
cholesterol levels had an increased risk of cancer incidence compared to the group with intermediate 
cholesterol levels (HR (95%CI) = 1.45 (1.05-2.01), P=0.02) or high cholesterol levels (HR (95%CI) 
= 1.90 (1.34-2.70), P<0.01). After adjustment for potential confounders, subjects with low 
cholesterol levels still had an increased risk for cancer incidence compared to subjects with 
intermediate cholesterol levels (HR (95%CI) =1.35 (0.97-1.89), P=0.08) or compared to subjects 
with high cholesterol levels (HR (95%CI) = 1.70 (1.16-2.50), P<0.01).  Results were similar for 
LDL cholesterol levels, subjects with low LDL cholesterol levels had an increased risk for cancer 
incidence compared to subjects with higher LDL cholesterol levels. Moreover, subjects with 
incident cancer decreased significantly more in cholesterol levels prior cancer diagnosis compared 
to subjects without incident cancer (mean (se) = -0.23 (0.05) vs -0.13 (0.01) respectively, P=0.05), 
this remained significant after adjustment for gender, age, and country (P=0.04). The association 
between ApoE genotype and cancer incidence presented a different picture (Table 3). E2+ carriers, 
with the lowest cholesterol levels, had no increased risk for cancer incidence compared to the E3/E3 
subject (HR (95%CI) = 0.90 (0.56-1.45), P=0.67) or to E4+ carriers (HR (95%CI) = 0.91 (0.53-
1.54), P=0.72).  
 
A similar trend was seen for cancer mortality as with cancer incidence (table 3). Subjects with low 
levels of plasma cholesterol had an increased risk of cancer mortality compared to intermediate 
levels of cholesterol (HR (95%CI) = 2.10 (1.27-3.50), P=<0.01) and high levels of cholesterol (HR 
(95%CI) = 2.03 (0.95-3.02), P<0.01). When we adjusted this association for the potential 
confounders, the results did not change. In the association with ApoE genotype and cancer mortality 
we found that ApoE2 carriers, who had the lowest plasma cholesterol levels, had a similar risk for 
cancer mortality compared to ApoE3/E3 carriers (HR (95%CI) = 0.88 (0.55-1.41), P=0.59) and 
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Discussion 
In this study we assessed the association between plasma cholesterol levels and cancer risk, free of 
confounding and reverse causality by using the method of Mendelian randomization.  
We found that subjects, when grouped by their baseline levels of cholesterol, had an increased 
cancer risk if the cholesterol levels were lower. This risk remained even after adjustment for 
potential confounders. However, when we categorized subjects according to their ApoE genotype, 
which also resulted in groups with significantly different cholesterol levels, no increased risk for 
cancer risk was observed between groups. These findings suggest that low levels of cholesterol are 
not causally related to an increased risk of cancer.  
 
If cholesterol is causally related to an increased risk of cancer, we would have found similar results 
for the association between plasma cholesterol levels and cancer risk as for the ApoE genotype and 
cancer risk. When we grouped subjects based on their cholesterol level, those in the low cholesterol 
group had an increased risk of cancer. However, when we grouped according to ApoE genotype, 
subjects in the ApoE2+ group had no increased risk of cancer, despite their significantly lower level 
of cholesterol. We were planning to formally test with statistical software using Mendelian 
randomization, whether the two different methods gave different results. However, to our 
knowledge, this is only possible for continuous outcome data. Since we have dichotomous outcome 
data, we were unable to formally test whether the two methods actually yielded different results. 
When we adjusted the association between plasma cholesterol levels and cancer for a wide range of 
potential confounders, including age, sex, current smoking, alcohol use, diabetes, myocardial 
infarction, and history of hypertension we still found a significant association between low 
cholesterol level and higher risk of cancer. Therefore, we think that that the association between low 
plasma cholesterol levels and increased risk for cancer is more likely to be due to reverse causality, 
and less so by confounding. 
 
Substantial evidence indicates that cancer can reduce plasma cholesterol levels prior to cancer 
diagnosis. This phenomenon is known as the preclinical cancer effect (7). The mechanism by which 
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cancer can lower plasma cholesterol is unclear. However, research into this mechanism has revealed 
that tumor cells need cholesterol for their growth and proliferation. Therefore there is an increased 
uptake of cholesterol from the blood by tumor cells (22;23). This might lead to lower plasma 
cholesterol levels prior to cancer diagnosis. Moreover, alterations in plasma lipids and lipoprotein 
fractions have been demonstrated in patients with acute leukemia and non-Hodgkin’s lymphoma 
(24;25).  Similarly, there is ample evidence, as recently reviewed (26) for an inverse relationship 
between the magnitude of inflammatory response and lipid levels in a variety of conditions such as 
sepsis, rheumatoid arthritis and other cancers: cholesterol levels are lowered in these illnesses but 
can increase dramatically and spontaneously with resolution of sepsis or with treatments which 
potently suppress the inflammatory response.   
 
In 1986 one of us (MBK) proposed to investigate the causality of cholesterol in cancer risk by 
making use of the ApoE genotype (16). He reasoned that if naturally low cholesterol favours tumour 
growth, then carriers of the ApoE2+ genotype, who have lower levels of plasma cholesterol, should 
have an increased risk of cancer. Until 2004 no one had taken up his idea (27). Now more than 20 
years after this initial idea we finally address the causality of cholesterol in the risk of cancer.  
 
There are some limitations to the use of the PROSPER study cohort. Subjects were selected to have 
a history of vascular disease or have an increased risk for such a disease. Although the frequencies 
of the ApoE genotypes in our study are similar to those in the general population, when 
extrapolating the results to the general population, the enrichment of cardiovascular disease in our 
study population should be kept in mind. Furthermore, we think that the association between plasma 
cholesterol and cancer risk is mostly affected by reverse causality, and less by confounding, because 
adjustment for potential confounders did not change the results. However, the number of 
confounders we have adjusted for might not be sufficient; it could be that there are still confounders 
that we do not know of. Therefore we cannot completely exclude the possibility that the association 
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Moreover, although our study was adequately powered to find a hazard ratio of 1.5 between 
cholesterol groups, it was relatively small to demonstrate equivalence between genotype groups. 
Given a 9% difference in cholesterol level between most extreme ApoE groups, the estimated 
difference in cancer risk would also be small. Therefore our study has a relatively low power, which 
is an important drawback of Mendelian randomization studies (28). Therefore we cannot state with 
absolute certainty that low cholesterol does not cause cancer. But given the fact that all hazard ratios 
are below unity, it is unlikely that low levels of cholesterol have a substantial impact on cancer risk.  
 
One strength of our study is that we have a follow-up period of 3.2 years and were able to track 
more than 95% of all participants over this time. Moreover, cancer incidence and mortality were 
main outcomes of our study and were precisely monitored, which increases the accuracy of this 
study accordingly.  
 
In conclusion, we have used the Mendelian randomization concept to suggest that the association 
between low plasma cholesterol and risk of cancer does not derive from a cause effect. Carriers of 
the ApoE2+ genotype, associated with low plasma cholesterol levels, had no increased risk of 
cancer. We therefore believe that subjects with low plasma cholesterol levels are not at an increased 
risk for cancer and that treatment with cholesterol lowering medications does not increase cancer 
risk by itself. 
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Main findings 
The general objective of this thesis was to investigate associations between genetic variants 
involved in inflammation and epigenetics and age-related diseases. First we analyzed genetic 
variation in genes related to inflammatory processes, since inflammation is known to play an 
important role in age-related diseases like cardiovascular disease, cognitive decline and cancer. 
Analysis of polymorphisms of the genes that are key for regulation of the immune response might 
clarify the patho-physiology of age-related diseases like atherosclerosis. Therefore, we analyzed the 
association between genetic variation in pro- and anti-inflammatory genes and cardiovascular 
disease (chapter 2 & 3), cognitive function (chapter 4 & 5), and cancer (chapter 6) 
 
In chapter 2 we investigated the relation between the C804A polymorphism in the pro-inflammatory 
gene Lymphotoxin-alpha (LTA) also known as Tumor Necrosis Factor-beta (TNF-β) and coronary 
and cerebrovascular events. The C804A polymorphism causes an amino-acid change from threonine 
(T) to asparagine (N) at codon 26 (1). The variant protein 26N is associated with a two-fold increase 
in the induction of cell-adhesion molecules in vascular smooth muscle cells (1). These adhesion 
molecules are implicated in cardiovascular disease which might explain the association of the 
polymorphisms in the LTA gene and the increased risk for incident stroke (2;3). Our results indicate 
that carriers of the 804A allele have an increased risk for the primary study endpoint consisting of 
coronary events and clinical strokes, primarily in men. Furthermore, we found that the association 
between the C804A polymorphism and the primary endpoint in males was mainly attributable to 
incident strokes.  
 
In chapter 3 we assessed the relation between four promoter polymorphisms in the interleukin-10 
(IL-10) gene and vascular events at old age. Carriers of the -2849AA genetype within the IL-10 
promoter region have an increased risk for vascular disease, coronary and cerebrovascular. In IL-10 
knock-out mice the absence of IL-10 leads to an increased susceptibility of atherosclerosis (4). 
Furthermore, a study using an overexpressing transgenic mice model and IL-10 null mice showed a 
marked difference in lesion size between the groups, the IL-10 null mice having far more lesion 
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formation when compared to the overexpressing mice model (5). We found that two of the main IL-
10 haplotypes showed significant associations with vascular diseases compared to the reference 
haplotype with no variants present. This provides evidence that not only pro-inflammatory 
processes contribute to atherosclerosis but that also anti-inflammatory cytokines are implicated in 
vascular disease. These findings support the hypothesis that genetic programming of the 
inflammatory response may be relevant to the pathogenesis of atherosclerosis. 
 
The relation between genetic variation in inflammatory genes and cognitive function was 
investigated in chapter 4 and 5. In chapter 4, we assessed the association between four 
polymorphisms within the ICE gene and cognitive function in an elderly population, since genetic 
variation in the gene coding for ICE influences expression and function of IL-1β. We found that two 
variants in the ICE gene significantly lowered IL-1beta levels, and that carriers of these variants 
performed better on all cognitive function tests. This indicates that low levels of the pro-
inflammatory IL-1beta might be protective for memory and learning deficits. These results are 
consistent with earlier findings on inhibition of ICE coinciding with lower IL-1beta levels in the 
hippocampus and improved memory (6). ICE inhibitors might therefore become a therapeutic target 
for subjects to prevent cognitive decline. 
 
In chapter 5, we found that genetic variation in the promoter region of the IL-10 gene is associated 
with decreased cognitive function in individuals without clinical evidence of a cerebrovascular 
event. This provides evidence that genetic variation in the IL-10 gene is a good marker for risk 
prediction of cognitive function. If these findings are confirmed and adequately explained on the 
basis of independent studies, screening patients for the IL-10 promoter polymorphisms may 
contribute to a better risk stratification of patients at increased risk for cognitive decline and 
additional preventive therapy may be warranted.  
 
We have assessed the association between circulating levels and innate production capacity of pro-
inflammatory cytokines in whole blood samples and cancer incidence and mortality in chapter 6. 
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High levels of the circulating inflammatory markers were associated with an increased risk of 
cancer incidence and death from cancer. However, high innate pro-inflammatory cytokine 
production capacity was only associated with an increased risk of death from cancer during follow-
up. This indicates that circulating markers of inflammation are increased in cancer patients, 
probably by autocrine production of the cancer cells themselves, and that therefore the relation 
between circulating inflammatory markers and incident cancer might be disturbed by reverse 
causality. However our main finding was that subjects with a pro-inflammatory trait, i.e. subjects 
with a high innate cytokine production level, had an increased risk of dying of the consequences of 
cancer when they had developed a tumor. Hence, it may be hypothesized that by administration of 
antibodies that bind pro-inflammatory cytokines, survival time of cancer patients might be 
extended.  
 
Furthermore, we studied genetic variation in genes related to epigenetics, to give additional insights 
into mechanisms that underlie age-related diseases. Since, epigenetics is a fairly new concept in the 
relation with age-related diseases, we have provided first evidence that this process can indeed play 
an important role in the patho-physiology of age-related diseases. 
 
In chapter 7, we investigated the association between genetic variation in the CREB Binding Protein 
(CBP) gene and cognitive function. Many experimental studies have investigated the role of CBP in 
memory formation and cognitive dysfunction in animals (7-10). CBP+/- mutant mice have normal 
short-term memory, but deficiencies in long-term memory, object recognition, and contextual 
memory tasks (11). Moreover, loss of one functional copy of the CBP gene in humans underlies all 
abnormalities in Rubinstein-Taybi Syndrome patients, including mental retardation (12;13). 
Therefore it is likely that polymorphisms in the CBP gene have an effect on cognitive function. We 
have demonstrated an association between two polymorphisms in the CBP gene and cognitive 
function in an elderly population. The variant alleles of the intron 4CT and intron 3AC 
polymorphisms were associated with better cognitive performance in all cognitive domains at 
baseline and in follow-up. Furthermore, the haplotype with the variant alleles of these two 
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polymorphisms also showed a protective effect on cognitive function in all cognitive domains. 
Future research is warranted to assess the functionality of these polymorphisms on the expression of 
CBP levels and how these polymorphisms affect the gene expression mediated by CBP. When 
confirmed, screening patients for the CBP polymorphisms may contribute to a better risk 
stratification of patients at risk for cognitive decline and may improve individual treatment. 
 
In chapter 8, we investigated the impact of genetic variation in the PCAF-gene on all-cause 
mortality, and mortality due to vascular events and cancer in the PROSPER-study and validated our 
findings in the WOSCOPS and GENDER study. We showed in these three large prospective studies 
that the -2481C allele in the PCAF promoter is associated with a significant survival advantage in 
elderly patients while carriers were protected against clinical and angiographic restenosis after 
percutaneous coronary intervention (PCI). Functional analysis showed that the -2481 G/C 
polymorphism is located in a functional region of the PCAF promoter, and modulation of PCAF 
gene expression was detectable in an animal model of reactive stenosis. Our observations promote 
the concept that epigenetic processes are under genetic control and that, other than environment, 
genetic variation in genes encoding HATs may determine susceptibility to coronary heart disease 
outcomes and mortality.  
 
In chapter 9, we used an innovative concept in genetic epidemiology. We assessed the association 
between plasma cholesterol levels and cancer risk, free from confounding and reverse causality, by 
a Mendelian randomization study design using the ApoE genotype. We found that subjects, when 
grouped by their baseline levels of cholesterol, had an increased cancer risk when the cholesterol 
levels were lower. This risk remained even after adjustment for potential confounders. However, 
when we categorized subjects according to their ApoE genotype, which also resulted in groups with 
significantly different cholesterol levels, no increased risk for cancer risk was observed between 
groups. These findings suggest that low levels of cholesterol are not causally related to an increased 
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Clinical implications 
We have shown that subjects carrying genetic variants coding for a high pro-inflammatory profile or 
a low anti-inflammatory profile have an increased risk to develop several age-related diseases. In 
the process of atherosclerosis, inflammatory mechanisms operate largely through cytokine secretion 
and their activation can cause plaque rupture, thrombosis, and acute ischemic symptoms (14-18). 
Anti-inflammatory and immunosuppressive mechanisms inhibit atherosclerosis and may be 
attractive targets for disease prevention and/or treatment (19). They include amongst others anti-
inflammatory cytokines, protective antibodies, and regulatory T cells, and may be induced by 
immunization. These therapies could also play an important role in delaying the process of 
cognitive decline in old age (20). For example, inhibition of ICE with ICE inhibitors have shown to 
reduce the IL-1β production in the brain (21), indicating a potential therapeutic role for ICE 
inhibitors in subjects with cognitive decline.  
 
Moreover, we have shown that besides inflammatory processes, epigenetic mechanisms could also 
play a role in age-related diseases. Epigenetic modifications, like histone acetylation, accumulate 
with ageing (22). It can be envisioned that when this accumulation comes to a halt, the development 
of age-related diseases might be delayed (23). Histone deacetylases (HDAC) inhibitors have been 
successfully introduced in clinical trials as anti-tumour agents. Recent findings identified HDACs as 
possible targets for therapy in cardiovascular disease (24). The investigators found that HDAC 
inhibition could reduce the size of myocardial infarction by ~50% in mice.  
A better understanding on the role of epigenetic processes in age-related diseases might provide 
novel opportunities to understand disease pathology. This would provide the necessary knowledge 
platform for design of alternative treatment strategies aimed at interfering in these epigenetic 
processes. 
 
Genetic epidemiology can also contribute to establishing the causal nature of environmentally 
modifiable risk factors, through the application of Mendelian randomization approaches. By making 
use of this Mendelian randomization approach we found that low cholesterol levels were not 
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causally associated with an increase in cancer risk. Low cholesterol levels are probably a result of 
an increased uptake of the cancer cells themselves. Cancer cells need cholesterol for their growth 
and proliferation (25;26). A sudden drop in plasma cholesterol levels can therefore be a predictive 
factor of an underlying tumour. Hence, in clinical practice, more attention could be paid to sudden 
drops in cholesterol levels as a prediction of cancer.  
 
Future research 
Mendelian randomization is a fairly new concept in genetic epidemiology. It has already proven to 
be a valuable tool, since Mendelian randomization provides an alternative way of dealing with the 
problems of causal inference in observational studies. Inferring causality from observational data is 
problematic as it is not always clear which of two associated variables is the cause and which is the 
effect, or whether both are common effects of a third unobserved variable, a confounder. In some 
instances the problem of causality and confounding can be resolved with randomized clinical trials, 
however this is not possible for a whole range of exposures like toxins and physical activity. For 
these questions Mendelian randomization can provide a solution.  
 
The Mendelian randomization approach has developed rapidly over the past 5 years, and proof of 
principle is now abundantly available. For example, the MTHFR C677T polymorphism, that 
determines homocysteine levels, shows a consistent causal relation with stroke as was also shown in 
observational studies (27). In the relation with CRP levels and metabolic syndrome, where several 
CRP polymorphisms were used as a proxy for CRP levels, no causal relation was found (28). 
Furthermore, genome wide association studies will provide us with new genetic variants as proxies 
for intermediate phenotypes for Mendelian Randomization studies. Therefore, Mendelian 
randomization should be applied more in future research (29). 
 
Genetic epidemiology has merely been based on investigating associations with genetic variation in 
genes related to the investigated mechanisms. This is called a candidate gene approach, which we 
also used in all studies reported in this thesis. However, most age-related diseases are not the result 
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of only one disturbance in one pathway. Age-related diseases are complex diseases where many 
pathways and mechanisms could play a role in the patho-physiology. To determine all mechanisms 
involved in age-related diseases, the candidate-gene approach is not sufficient. Nowadays, the 
genetic technologies are much more advanced in a way that we can screen the whole genome. These 
genome wide associations studies (GWA) are used to discover more genetic variants in various, 
mostly unknown, pathways associated with complex age-related diseases. When these genetic 
variants are being discovered, we can make a better risk profile per individual, and eventually 
implement personalized therapy based on the individual genetic risk profile. 
 
One example of a new genetic study is the PHASE project (PHArmacogenomic study of Statins in 
the Elderly at risk for cardiovascular disease), which started in January 2009. In this project we 
perform a genome-wide scan in all 5804 participants of the PROSPER study in order to discover the 
genetic variation responsible for variation in lowering low-density lipoprotein levels, variation in 
clinical outcome, like cardiovascular disease, cancer and cognitive decline, and for the occurrence 
of adverse effects. By increasing the knowledge of which genetic variation is responsible for the 
variation in drug response, we can develop personalized cholesterol lowering drug therapy based on 
an individual’s genetic make-up to obtain optimal cardiovascular event reduction, minimal side 
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Het aantal ouderen boven de 70 jaar is de laatste jaren toegenomen. Dit komt door een significante 
reductie van sterfte op alle leeftijden waardoor een toename van de gemiddelde en maximale 
levensverwachting heeft plaatsgevonden. Een hoge leeftijd is geassocieerd met een verhoogde kans 
op ziekte en sterfte. De verhoogde sterfte bij ouderen aan verschillende ouderdomsziekten zoals 
infectieziekten, hart- en vaatziekten en kanker kan onder andere herleid worden naar een verstoorde 
respons van het immuunsysteem. Andere mechanismes die mogelijk veranderen met leeftijd en 
daardoor leiden tot ouderdomsziekten zijn nog niet bekend. Epigenetica is een dergelijk 
mechanisme dat wel kan veranderen met de leeftijd, maar waarvan nog niet bekend is of deze 
veranderingen ook leiden tot verschillende ouderdomsziekten. Het doel van deze thesis was om 
associaties te vinden tussen genetische variaties in genen betrokken bij het immuunsysteem en 
genen betrokken bij epigenetica en de verschillende ouderdomsziekten om meer inzicht te 
verkrijgen in de patho-fysiologische mechanismes van deze ziekten. Voor alle onderzoeken hebben 
we data gebruikt van de deelnemers aan de PROSpective Study of Pravastatin in the Elderly at Risk 
(PROSPER).  
 
In hoofdstuk 2 onderzochten we de associatie tussen het C804A polymorfisme in het gen 
Lymfotoxin-alpha en coronaire ziekten en beroertes. Hieruit is gebleken dat dragers van dit 
polymorfisme een verhoogd risico hebben op het krijgen van een hartaanval of beroerte. Na 
stratificatie bleek dit effect het sterkst voor beroertes bij mannen. Aangezien Lymfotoxin-alpha een 
pro-inflammatoir eiwit is, betrokken bij de inductie van celadhesie moleculen in vasculaire gladde 
spiercellen, toonden we hiermee aan dat pro-inflammatoire markers risicofactoren kunnen zijn voor 
hart- en vaatziekten. 
 
De relatie tussen 4 polymorfismes in het interleukine-10 (IL-10) gen en cardiovasculaire incidenten 
op oude leeftijd wordt beschreven in hoofdstuk 3. IL-10 is anti-inflammatoir omdat het de synthese 
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van pro-inflammatoire eiwitten remt. In IL-10 knock-out muizen is aangetoond dat de afwezigheid 
van IL-10 leidt tot een verhoogd risico op atherosclerose, een van de belangrijkste oorzaken van 
hart- en vaatziekten. Wij hebben aangetoond dat dragers van genetische varianten in het IL-10 gen, 
die een lagere expressie hebben van IL-10 eiwitten, een verhoogd risico hebben op het krijgen van 
hart- en vaatziekten. Hiermee lieten we zien dat niet alleen pro-inflammatoire eiwitten betrokken 
zijn bij hart- en vaatziekten maar dat ook een verlaagde expressie van een anti-inflammatoir eiwit 
een verhoogd risico geeft op hart- en vaatziekten. 
 
In hoofdstuk 4 en 5 bekeken we de relatie tussen genen betrokken bij inflammatoire processen en 
cognitieve functie. De associatie tussen 4 polymorfismes in het interleukine-1-beta converting 
enzyme (ICE) gen en cognitieve achteruitgang is onderzocht in hoofdstuk 4. ICE is een eiwit dat de 
expressie en functie van het pro-inflammatoire cytokine interleukin-1-beta (IL-1β) beïnvloedt. Wij 
hebben gevonden dat twee variaties in het ICE gen leiden tot significant lagere IL-1β levels in het 
bloed. Dragers van deze varianten presteerden significant beter op alle cognitieve functietesten 
tijdens de 3,5 jaar follow-up. Deze resultaten suggereren dat lage levels van het pro-inflammatoire 
cytokine IL-1β beschermend kunnen zijn tegen cognitieve achteruitgang. Onze bevindingen zijn 
consistent met eerdere bevindingen in de literatuur. In muismodellen is gevonden dat wanneer het 
eiwit ICE geremd wordt, dit resulteert in lagere levels van IL-1β en een verbetering van het 
geheugen. ICE-remmers kunnen daarom gezien worden als een potentieel belangrijke target om 
cognitieve achteruitgang bij ouderen tegen te gaan. 
 
In hoofdstuk 5 vonden we dat die 4 polymorfismes in het IL-10 gen niet alleen geassocieerd zijn 
met hart- en vaatziekten maar ook met een verslechterde cognitieve functie, onafhankelijk van het 
wel of niet krijgen van een beroerte. Deze studie laat zien dat genetische variatie in het IL-10 gen 
gebruikt kan worden als een risico marker om de mate van cognitieve functie in te schatten. 
Wanneer deze bevindingen gerepliceerd worden en er voldoende informatie over bekend is, zal 
screening van de IL-10 polymorfismes kunnen leiden tot een juiste risicostratificatie van patiënten 
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met een verhoogd risico op cognitieve achteruitgang. Hierdoor kan er naar een passende individuele 
therapie worden gezocht. 
 
De relatie tussen circulerende levels en de van nature aanwezige productiecapaciteit van 
verschillende pro-inflammatoire cytokines en kanker incidentie en mortaliteit wordt beschreven in 
hoofdstuk 6. Hoge circulerende levels van deze pro-inflammatoire markers waren geassocieerd met 
een verhoogd risico op kanker incidentie en mortaliteit. Echter, een verhoogde productiecapaciteit 
was alleen geassocieerd met een verhoogd risico op kanker mortaliteit. Deze bevinding suggereert 
dat circulerende inflammatoire markers verhoogd zijn in patiënten met kanker, waarschijnlijk door 
autocriene productie van de kankercellen, en dat de relatie tussen circulerende markers en kanker 
incidentie waarschijnlijk verstoord is door omgekeerde oorzakelijkheid. Onze belangrijkste 
bevinding is dat mensen met een verhoogd van nature aanwezige productiecapaciteit van pro-
inflammatoire cytokines, dus mensen met sterk pro-inflammatoir profiel, een verhoogd risico 
hebben om te sterven wanneer zij een tumor hebben ontwikkeld. Derhalve suggereren wij dat de 
overlevingsduur van kanker patiënten waarschijnlijk verlengd zou kunnen worden met middelen 
gericht tegen pro-inflammatoire cytokines.   
 
Hierboven zijn de studies beschreven die de relatie tussen het immuunsysteem en ouderdomsziekten 
onderzochten. In hoofdstuk 7 en 8 beschrijven we twee studies die de relatie onderzoeken tussen 
genetische variatie in genen betrokken bij epigenetica en ouderdomsziekten om zo meer inzicht te 
krijgen in de patho-fysiologie van deze ziekten. Omdat epigenetica pas recent gelinkt wordt aan 
ouderdomsziekten, zijn wij de eersten die met deze studies bewijs leveren dat epigenetica inderdaad 
een belangrijke rol speelt in de patho-fysiologie van ouderdomsziekten.  
 
In hoofdstuk 7 beschrijven we de associatie tussen genetische variatie in het CREB binding protein 
(CBP) gen en cognitieve functie. Meerdere studies in diermodellen hebben deze relatie al 
onderzocht. Hieruit bleek dat CBP+/- gemuteerde muizen gebreken hadden in hun lange termijn 
geheugen, object herkenning en geheugentaken. In mensen leidt het verlies van 1 kopie van het 
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CBP gen tot alle abnormaliteiten die bij het Rubinstein-Taybi syndroom voorkomen, waaronder 
mentale retardatie. Dit maakt het aannemelijk dat polymorfismes in het CBP gen een effect hebben 
op cognitieve functie bij oudere mensen. We hebben aangetoond dat 2 polymorfismes (intron 4CT 
en intron 3AC) associëren met betere cognitieve functie in alle domeinen. Verder hebben we ook 
laten zien dat dragers van het haplotype met deze varianten beschermd waren tegen cognitieve 
achteruitgang. Dit is een eerste aanwijzing dat het CBP gen betrokken is bij cognitieve functie bij 
ouderen. Verder onderzoek moet nog uitgevoerd worden naar de effecten van de twee 
polymorfismes op de expressie van CBP levels en hoe zij de gen expressie, gemediëerd door CBP, 
veranderen.  
 
In hoofdstuk 8 hebben we het effect van genetische variatie in het PCAF gen op algemene en 
vasculaire mortaliteit onderzocht in 3 onafhankelijke studies, de PROSPER studie, de GENDER 
studie en de WOSCOPS studie. In deze drie studies vonden we dat mensen met het -2481C allel in 
de PCAF promoter een significant overlevingsvoordeel hebben en dat ze beschermd zijn tegen het 
ontstaan van klinische restenose. Uit een functionele studie bleek verder dat dit polymorfisme in een 
functioneel gebied van de PCAF promoter ligt en dat in een diermodel van restenose de mate van 
PCAF expressie was veranderd. Al deze bevindingen laten zien dat ook epigenetische processen een 
rol kunnen spelen bij hart- en vaatziekten en overleving. 
 
In hoofdstuk 9 hebben we een vrij nieuwe methode gebruikt in de genetische epidemiologie. We 
hebben de associatie tussen plasma cholesterol levels and kanker risico onderzocht vrij van 
confounding en omgekeerde oorzakelijkheid door middel van een Mendeliaanse randomisatie 
methode gebruikmakend van het APOE genotype. We vonden dat mensen, gegroepeerd naar hun 
cholesterol waarden, een hoger risico hadden voor kanker wanneer de cholesterol waarden het 
laagst waren. Deze associatie bleef bestaan na correctie voor verschillende potentiële confounders. 
Daarentegen, wanneer we mensen groepeerden naar aanleiding van hun APOE genotype, dat 
resulteert in groepen met een verschillend cholesterol niveau, vonden we geen risicoverschil voor 
kanker in de verschillende groepen. Deze resultaten suggereren dat lage cholesterol niveaus niet 
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causaal geassocieerd zijn met kanker risico en dat therapie met cholesterol verlagende middelen het 
risico op kanker niet verhoogt. 
 
Conclusie 
In deze thesis hebben we studies beschreven die de relatie tussen inflammatie, epigenetica en 
ouderdomsziekten hebben onderzocht. We vonden dat pro- en anti-inflammatoire markers 
belangrijke risicofactoren kunnen zijn voor hart- en vaatziekten, voor cognitieve achteruitgang en 
voor kanker. Verder hebben we ook laten zien dat genetische variaties betrokken bij epigenetica een 
rol spelen in hart- en vaatziekten en cognitieve achteruitgang, wat impliceert dat ook epigenetische 
processen belangrijk zijn bij de patho-fysiologische processen van ouderdomsziekten. Echter het 
precieze biologische mechanisme hierachter is nog niet bekend. 
 
In deze thesis hebben we gebruikt gemaakt van een kandidaat-gen methode om de associaties tussen 
genetica en ouderdomsziekten te onderzoeken. Daarbij hebben we biologische mechanismes 
onderzocht waarvan het vermoeden al bestond dat ze betrokken kunnen zijn bij de patho-fysiologie 
van de ouderdomsziekten. Maar ouderdomsziekten zijn complexe ziektebeelden waar meerdere 
mechanismes tegelijkertijd een belangrijke rol kunnen spelen. Om ook de nog onbekende 
mechanismes te ontrafelen, wordt er tegenwoordig gebruik gemaakt van een methode om het hele 
genoom in één keer te screenen, namelijk de ‘Genome Wide Associations (GWA) studies’. In januari 
2009 is ook een GWA analyse gestart binnen de PROSPER studie, namelijk het ‘PHASE’ project. 
Met dit project willen we nieuwe genen en mechanismes ontdekken betrokken bij onder andere 
hart- en vaatziekten, cognitieve achteruitgang en kanker, zodat we nog meer inzicht krijgen in de 
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